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Thesis at a glance 
Figure 1 depicts the relationships between the studies. The aim of this thesis was to investigate pain 
and sensitization in osteoarthritis (OA)-related post-operative pain (Study I), compare this to painful 
knee OA and explore whether the spreading of sensitization differs within the patient populations 
based on local knee sensitization (Study II), and investigate whether multimodal non-surgical 
treatment improves pain and sensitization outcomes in patients with knee OA (Study III). 
 
Study I.  
 
 
 
Patients with pain after revision of total knee 
arthroplasty (re-TKA) compared to those 
without pain demonstrated: 
 
 More body sites with pain; and 
 
 More pronounced widespread sensitization 
as indicated by 
 decreased pressure pain thresholds and 
pressure tolerance thresholds;  
 facilitated temporal summation, and  
 impaired conditioned pain modulation 
(Figure 2).
1 
                                                          
1 Mean pressure pain thresholds (PPT) manually assessed in patients with (A) and without pain (B) after revision total 
knee arthroplasty (re-TKA). The PPTs were recorded before, during, and after conditioned pain modulation by tonic 
arm pain in the knee region, at the lower leg, and at the forearm. The assessments were averaged between the leg with 
re-TKA and the contralateral leg. PPTs were significantly different during compared to before the painful conditioning 
stimulation (*, P < 0.05). Error bars indicate SEM.  
Figure 2. Conditioned pain modulation.1  
Figure 1. Continuum of osteoarthritis (OA)-related pain and sensitization 
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Study II.  
Despite similar pain intensities, patients: 
 
 with post-operative pain had more 
facilitated temporal summation than those 
with knee OA  
 
 with high knee pain sensitivity showed a 
more prominent spreading of sensitization 
than those with low knee pain sensitivity 
(Figure 3).2  
 
 
 
 
 
Study III.  
Patients undergoing a combined, 
individualized treatment consisting of 
education, neuromuscular exercise, weight 
loss, insoles, and pain medication have 
greater improvements after 3 months than 
patients receiving usual care in: 
 
 Peak pain intensity and pain intensity 
after 30 min of walking; and 
 
 Number of body sites with pain;  
 
 But not in sensitization locally at the knee 
or at sites distantly to the knee (both groups improved; Figure 4).3 
 
                                                          
2 Mean pressure pain thresholds assessed at the lower leg and at the forearm using a handheld pressure algometer. 
Group 1 (n = 26): knee OA pain and low knee pain sensitivity. Group 2 (n = 27): knee OA pain and high knee pain 
sensitivity. Group 3 (n = 10): pain after revision total knee arthroplasty (re-TKA) and low knee pain sensitivity. Group 
4 (n = 10): pain after re-TKA and high knee pain sensitivity. Significantly lower PPTs were found in group 4 compared 
to PPTs in groups 1 to 3 (*, P < 0.05) and in groups 2 and 3 compared to group 1 (#, P < 0.05) on both sites (lower leg 
and forearm). Error bars indicate SEM. 
3 Mean pressure pain thresholds (PPT) measured in kPa using a handheld algometer from the knee, lower leg, and 
forearm. Significantly higher PPTs (*; P < 0.05) were found at all sites after 3 months in both the group undergoing the 
non-surgical treatment program (MEDIC) and the usual care group. Error bars indicate 95% confidence intervals. 
Figure 4. Pressure pain thresholds from the most affected 
side.3  
Figure 3. Pressure pain thresholds.2  
 6 Pain and sensitization in knee osteoarthritis and persistent post-operative pain 
 
Acknowledgements 
First of all, I would like to thank all the patients participating in the studies, senior therapist Jan 
Kjærsgaard and the rest of the Department of Occupational Therapy and Physiotherapy, the 
orthopedic surgeons and other health care personnel from the Department of Orthopaedic Surgery, 
and the study funders; without their participation, engagement, and willingness to help the studies 
would never have been completed.  
I am very grateful for the hard work that my supervisors have put into the project: orthopedic 
surgeon Sten Rasmussen for always being available to discuss minor and major issues, Professor 
Ewa Roos for her methodological and OA-related expertise that always raised the quality of the 
studies yet another level, Professor Lars Arendt-Nielsen for his impressive knowledge and help 
within the field of pain research, and orthopedic surgeon Mogens Berg Laursen for facilitating and 
supporting the completion of the studies. 
Furthermore, I would like to thank orthopedic surgeon Ole Simonsen for his continuing spirit and 
enthusiasm within research and for always being there for me in all aspects of the career process, 
postdoc Michael Skovdal Rathleff for his commitment to the projects, biostatistician Martin Berg 
Johansen for statistical advice, and Professor Thomas Graven-Nielsen for support and important 
feedback on the design and reporting of the studies. 
I would also like to acknowledge Anders Bundgaard Lind, Anders Norge Jensen, Anna Emilie 
Livbjerg, Dorte Rasmussen, Helle Mohr Brøcher, Henriette Duve, Janus Duus Christiansen, 
Josephine Nielsen, Kate Mcgirr, Lasse Lengsø, Lonneke Hjermitslev, Malene Daugaard, Maria 
Helena Odefey, Mette Bøgedal, Mikkel Simonsen, Niels Balslev, Rikke Elholm Jensen, and Svend 
Lyhne for helping with the administration, data collection, data entry, and treatment in study III.  
Last but certainly not least, I would like to express my deepest gratitude toward my loving wife and 
son, Naja and Carl, who have had to put up with their husband and father spending so much time on 
research. Naja, I truly appreciate all the times you have listened and discussed study- and work-
related issues and sacrificed yourself for me, and I hope that I will be able to give you the same in 
return in the future.  
 
 
 
 
 
 
  
 
7 Abbreviations 
Abbreviations 
ADL Activities of Daily Living 
ANOVA ANalysis Of VAriance ANOVA 
BMI Body Mass Index 
CI Confidence Interval 
CPM Conditioned Pain Modulation 
EULAR The European League Against Rheumatism 
HSD Honest Significant Difference 
IASP The International Association for the Study of Pain 
KOOS The Knee Injury and Osteoarthritis Outcome Score 
MA Meta-Analysis 
NEMEX The NEuroMuscular EXercise training program 
NSAID Non-Steroidal Anti Inflammatory Drug 
OA Osteoarthritis 
OARSI Osteoarthritis Research Society International 
PPP Persistent Post-operative Pain 
PPT Pressure Pain Threshold 
PROM Patient-Reported Outcome Measures 
PTT Pain Tolerance Threshold 
QOL Quality of Life 
QST Quantitative Sensory Testing 
RCT Randomized Controlled Trial 
Re-TKA Revision Total Knee Arthroplasty 
RM Repeated Measures 
SD Standard Deviation 
SEM Standard Error of the Mean 
SMD Standardized Mean Difference 
TA  Tibialis Anterior Muscle 
TENS Transcutaneous Electrical Nerve Stimulation 
TKA Total Knee Arthroplasty 
VAS Visual Analog Scale 
WOMAC The Western Ontario and McMaster Universities Osteoarthritis Index 
YLD Years Lived with Disability 
 
 
 8 Pain and sensitization in knee osteoarthritis and persistent post-operative pain 
1. Background 
1.1. Knee osteoarthritis (OA): magnitude and burden 
OA affects 20% of the Danish population (897,000 Danes), making it the 2nd most common disease 
ahead of cardiovascular disease, diabetes, and cancer1, and costs  Danish society DKK 11.5 billion 
annually (corresponding to EUR 1.54 billion)2. The Global Burden of Disease study has estimated 
that OA is the 11th highest contributor to global disability out of a total of 291 conditions, and that 
the years lived with disability related to the disease are 17.1 millions3, 4. Due to methodological 
issues concerning the Global Burden of Disease study (e.g. a conservative case definition and the 
restriction to only include the hip and the knee) the study likely underestimated the burden of OA4. 
Additionally, knee and hip OA are associated with an increased risk of all-cause mortality, with 
diabetes, cardiovascular disease, cancer and walking disability as the strongest risk factors for 
death, potentially due to the sedentary and inactive lifestyle attributed to OA-related pain5.  
Even though OA-related pain is highly prevalent in the elderly, with over 40% of those aged 65 
years or older having hip or knee pain6, it is not only a disease of the elderly. In Denmark, OA rises 
abruptly from number 74 on the cause-ranking of years lived with disability (YLD) at ages 30 to 34 
to number 12 at ages 45 to 498. The impact of OA on those still in the labor market is further 
highlighted by the fact that patients with physician-diagnosed knee OA have a twofold risk of sick 
leave and up to a 50% increased risk of disability pension compared to the general population7.  
This underlines the major impact of OA on society and those affected by it, which is further 
substantiated by the fact that the prevalence of symptomatic OA has doubled in women and tripled 
in men during the last 20 years8 and is expected to increase substantially in the future9, and that OA 
has increased the health care expenditure by $185.5 billion per year in the US10 in recent years. 
1.2. Knee OA pathology, symptoms, and diagnosis 
1.2.1. Knee OA pathology 
OA is a degenerative, usually progressive, joint disease affecting synovial joints11, most frequently 
the knees, hips, hands, and spine12. Pathologically, the disease is characterized by local areas of 
damaged articular cartilage, typically in load-bearing areas, changes in the subchondral bone, 
osteophytes at the margins of the joint, some degree of synovitis, and thickening of the joint 
capsule12. It is the results of the failed regeneration of joint damage due to stresses arising from 
biomechanical13, 14, biochemical15, and/or genetic16 factors. The stress is initiated by abnormalities in 
the tissues of the joint, including the cartilage11, subchondral bone17-19, joint ligaments11, menisci20, 21, 
periarticular muscles22, peripheral nerves11, and/or synovium23, 24. These abnormalities are likely to 
differ depending on the joint affected and whether more than one compartment and joint are 
affected, highlighting the complexity of the disease11.  
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1.2.1. Knee OA symptoms 
The initial clinical characteristics of knee OA are, most often, usage-related pain and/or functional 
limitations25. Other typical symptoms and clinical features are pain worsening during the day that is 
relieved by rest25, morning or inactivity stiffness25, reduced range of motion12, swelling12, crepitus12, 
a feeling of giving way26, instability27, impaired postural balance28, 29 and, more recently identified, 
lack of knee confidence30, 31. OA symptoms are often intermittent and vary with regard to both their 
severity and the time it takes the disease to progress25. In more advanced stages of knee OA, the 
pain is typically more persistent at rest and at night25. Due to the symptoms, reduced participation in 
daily activities and a downward spiral with regards to fatigue, mood, sleep, and quality of life is 
common in knee OA32, 33.  
Encompassing all symptoms in the clinical assessment of the patient with knee OA is difficult. 
Recent research has emphasized that patient-reported outcome measures (PROM) should be applied 
to get a comprehensive overview of the individual patient and outcome from a given treatment. 
Instruments used for this purpose should be valid, reliable, and responsive and include disease-
specific measures such as the Knee Injury and Osteoarthritis Outcome Score (KOOS)34, 35 and the 
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)36 and generic 
measures such as EQ-5D 5 Dimensional form37 and SF-3638, 39. A more thorough description of the 
measures of symptoms is outside the scope of this thesis; please refer to overview papers such as 
that of Collins & Roos 201240. 
1.2.1. Knee OA diagnosis 
According to the European League Against Rheumatism (EULAR)25, a confident diagnosis of knee 
OA can be given in adults above 40 years of age if the patient has: 
 usage-related knee pain; 
 only short-lived morning stiffness; 
  functional limitation; and  
 one or more typical examination findings: 
o crepitus 
o restricted movement 
o bony enlargement 
 
However, if a patient has knee pain but does not fulfill all criteria, they can still have OA25. This is 
especially important to recognize if early treatment should be able to have an impact on the future 
burden of the disease41. 
This means that the diagnosis of knee OA can be made on a clinical basis, without radiographs, and 
is even valid if radiographs show no signs of OA25. However, in clinical practice radiographic 
examinations are often performed to support the diagnosis, despite the fact that the discrepancy 
between symptoms and radiographic severity is well known42 and that as little as 0.5% of all 
radiographs reveal treatment changing pathology43. This suggests that routine radiographic 
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examination is outdated and only applicable if an orthopedic surgeon is considering surgery, such as 
osteotomy and joint replacement12. If the radiographic severity of the disease needs to be 
characterized for clinical or research purposes, several classification systems exists44-47, with the 
Kellgren-Lawrence scale being the most commonly applied (0-4, from no OA to severe OA)44, 45. 
When a definite diagnosis of OA is needed, a score ≥2 is recommended, while a score of ≥1 can be 
used to distinguish between no OA and possible OA48. 
1.3. Pain and sensitization in Knee OA 
1.3.1. Pain in knee OA 
As presented in section “1.2. Knee OA pathology, symptoms, and diagnosis”, knee OA symptoms 
are many and vary widely within and between subjects. However, the hallmark symptom of OA is 
pain12, 49. Despite an improved understanding of pain over the past decades, the pathophysiology of 
OA pain remains poorly understood50. The nociceptive input in knee OA could originate from 
inflammation of the synovium, stretching of the joint capsule, raised intraosseous pressure in the 
subchondral bone, elevation of periosteum by osteophyte growth, sensitization of the central 
nervous system and/or periarticular tissues51, 52. In contrast to the classical 16th century Cartesian 
understanding of pain, it is now recognized that pain is complex and multidimensional and 
influenced by several modulating factors from the nociceptive input to the actual sensation of pain 
in the brain12, 50, 53. 
When evaluating pain, several different measures that encompass the complexity of pain should be 
used54. Besides measures of function, depression, and other symptoms, such measures include the 
evaluation of pain intensity using a visual analog scale55, the usage of pain medication54, duration of 
pain54, location and pattern of pain56, 57, and spreading of pain58. For a thorough description of 
measures of pain, please refer to overview papers such as those of Dworkin et al. 200554 and 
Hawker et al. 201155.  
1.3.2. Sensitization in knee OA 
In recent years, a mechanism-based approach to pain, which includes a focus on sensitization, has 
gained interest and is widely accepted and recommended to improve the understanding of pain59. 
According to the International Association for the Study of Pain (IASP)60, sensitization can be 
defined as “Increased responsiveness of nociceptive neurons to their normal input, and/or 
recruitment of a response to normally subthreshold inputs”, with peripheral sensitization defined as 
an increased response and reduced thresholds of nociceptive neurons in the periphery and central 
sensitization defined as an increased response of the nociceptive neurons to normal or subthreshold 
afferent input in the central nervous system. Peripheral and central sensitization are important 
aspects influencing the sensation of pain12, 50, 53. This is also the case with knee OA pain, where 
sensitization is known to be a prominent mechanism59, 61, and factors outside the joint (such as 
sensitization and periarticular structures) seem important for the maintenance of pain61-64.  
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Recent research suggests that musculoskeletal pain spreads over time, influenced by both the 
intensity65 and duration66 of the pain, due to central sensitization59, 67. This implies that a given pain 
condition or tissue damage spreads from a local area at the start (e.g. the patella tendon), to regional 
areas (e.g. the knee and inferior and superior parts of the leg), and ends up being chronic/persistent 
and widespread59, 67. It has been suggested that the transition of pain from acute to widespread is 
initiated by tissue stress (i.e. tissue damage) that leads to excitation and peripheral sensitization of 
the nociceptors, causing sufficient nociceptive input to the central nervous system that again leads 
to central sensitization of dorsal horn neurons and/or at higher brain centers67.The central 
sensitization of the dorsal horn neurons is characterized by prolonged neuronal discharges, 
increased pain sensitivity (hyperalgesia), response to non-painful stimuli (allodynia), and expansion 
of the receptive field68, 69. Furthermore, after (or at the same time as) the sensitization of second-
order neurons, a reorganization of the higher brain centers may take place, all together ultimately 
leading to widespread pain59, 67. 
Quantitative sensory testing (QST) represents a particular applicable method to assess sensitization 
in knee OA that uses a mechanism-based approach70. By assessing the somatosensory response 
evoked by applying controlled noxious or innocuous stimuli (e.g. using a pressure algometer) it is 
possible to quantify sensitization in a patient67, 71. Even though the experimental test stimulus gives a 
different pain experience for the patient than does the disease-related pain experience, it offers 
translational information on pain mechanism, with the potential to affect the management of the 
disease67. Just as the assessment of pain needs to be multidimensional, the quantification of 
sensitization should preferably be multidimensional by including various stimulus modalities 
(mechanical (e.g. by pressure), chemical (e.g. by ischemia), electrical, etc.) and assessing different 
pain mechanisms (hyperalgesia, temporal summation, conditioned pain modulation (CPM), the 
spread of sensitization, etc.)67, 72. Since mechanical stimuli, in particular pressure, are by far the most 
commonly applied modality in knee OA70, 73, this will be the focus of the rest of this section. 
In knee OA, increased pain sensitivity (hyperalgesia) has typically been evaluated using pressure 
pain thresholds (PPTs)70, 73, defined as the pressure at which the patient feels the pressure change to 
pain61. Increased pain sensitivity found locally at the affected knee (and in adjacent body parts) is 
associated with peripheral and central sensitization, while increased pain sensitivity distantly from 
the knee reflects generalized central sensitization  (spreading sensitization)59. This has previously 
been demonstrated in knee OA patients compared to healthy controls61-63, 74-77. Handheld pressure 
algometry has traditionally been used to evaluate PPT, but more recently cuff algometry, a method 
for investigating deep tissue pain sensitivity and central mechanisms that is less influenced  by 
intertester bias than handheld pressure algometry78, has been used in knee OA63, 64. Cuff algometry 
can also be applied to assess pain tolerance thresholds (PTT), defined as the pressure at which the 
pain is intolerable64. 
Temporal summation of pain, another pain mechanism, is the perceptual correlate in humans 
thought to mimic the initial phase of the wind-up process in dorsal horn neurons. Temporal 
summation can be assessed by applying ten sequential pressure stimulations at the level of the 
pressure pain threshold. The patients then rate their pain intensity continuously during the 
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sequential stimulation on an electronic VAS64. In chronic musculoskeletal pain such as OA and 
fibromyalgia, temporal summation to repetitive pressure pain stimulations has been demonstrated to 
be facilitated compared to healthy controls61, 79 due to sensitized central mechanisms. In patients 
with chronic painful knee OA, higher clinical pain intensities and longer pain durations caused 
relatively more temporal summation of pain compared with patients with shorter duration and less 
pain61. Furthermore, the extent of hyperalgesia61, 63, 64 and temporal summation61, 64 are related to 
higher pain intensities. Thus, OA disease progression seems better associated with pain and 
sensitization than with the actual joint destruction assessed by radiological scorings61.  
Another important pain mechanism associated with sensitization is the descending inhibitory and 
facilitatory modulation of the peripheral nociceptive inputs in the dorsal horn neurons59, 80. CPM is a 
manifestation of this modulation which can be assessed in patients and is characterized by a 
changed response to a painful test-stimulus when another painful conditioning stimulus is applied81. 
CPM is impaired in chronic pain disorders such as knee and hip OA61, 63, 82, temporomandibular joint 
disorders83, and fibromyalgia84, 85.  
For a more thorough description of sensitization and measures of sensitization, please refer to 
overview papers such as those of Graven-Nielsen 200672, Arendt-Nielsen & Graven-Nielsen 201159, 
and Graven-Nielsen & Arendt-Nielsen 201067 and for more a comprehensive overview of 
sensitization in knee OA, see Suokas et al. 201270 and Lluch et al. 201473. 
1.4. Treatment of knee OA 
 
 
 
 
 
 
 
 
 
 
 
No cure exists for knee OA, which is why the treatment is aimed at improving symptoms and 
preventing further progression of the disease. Due to the future burden of the disease, the need for a 
Figure 5. Osteoarthritis treatment pyramid (reprint from86, permission to reuse has 
been obtained). While all patients should be offered first line treatment, only some need 
second line treatment, and a few will need surgery (third line treatment). *Passive 
treatments are manual therapy, acupuncture, and other treatments given by a therapist not 
requiring an active effort by the patient. Only if the lower level of the pyramid is not 
sufficient in controlling/reducing the symptoms should the next level be considered. 
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paradigm shift toward early treatment is evident41. The treatment can be divided into three overall 
categories (first line, second line, and third line treatment) based on the recommended order of 
initiation (Figure 5)86. As recommend by the international organizations dealing with OA, 
EULAR87, and the Osteoarthritis Research Society International (OARSI)88, the core treatment (first 
line treatment) that should be offered as an individualized combined treatment is education, 
exercise, and weight loss (if needed), while other non-surgical treatments (second line treatment) 
can be added if needed, and only after this should surgical treatments  be considered (third line 
treatment). However, despite the recommendations, the combined efficacy of the recommended 
treatments has yet to be investigated. Figure 6 summarizes the effect sizes demonstrated in meta-
analyses of randomized controlled trials (RCTs)88, 89 for frequently applied first, second, and third 
line treatments. 
 
1.4.1. First line treatment of knee OA 
Education/self-management is considered a core element of first line treatment of knee OA87, 88.  
Despite small to moderate effect sizes (Figure 6)88, 91, 92, which may have arisen because the efficacy 
on pain and function were measured rather than the efficacy of education on anxiety, self-efficacy, 
adherence to exercise, etc., education is recognized as an important aspect of the treatment due to 
the central role of the patient in the treatment of the disease87. Since the two other aspects of first 
line treatment (exercise and weight loss) will only be beneficial if the patient is committed to the 
Figure 6. Effect sizes for treatment of knee osteoarthritis (based on meta-analyses (MA) of randomized controlled 
trials (RCT) 88, 89). A larger effect size (SMD) indicates a larger effect. SMDs can be clinically interpreted as  ≥0.2: 
small,  ≥0.5: moderate, and  ≥ 0.8: large90. Two MAs91, 92 have produced different results for education, therefore both are 
presented. No RCTs have been conducted for total knee arthroplasty124, which is why the SMD is not known. Error bars 
indicate 95% CI. 
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treatment, it is important that it is delivered together with an educational aspect that teaches the 
patient about the disease, that pain during exercise is okay as long as it subsides, and the importance 
of the lifelong continuation of treatments such as exercise93, 94. Furthermore, long-term efficacy is 
dependent on the patient’s adherence to the treatment after the intervention period95. So far, no 
optimal educational program has been indentified for patients with knee OA92, but experiences from 
an implementation initiative in Denmark have shown promising results from a combined treatment 
of exercise and three 1.5-hour sessions of patient education, two led by a physiotherapist and one 
led by a previous participant in the treatment program. The education aims to improve the 
knowledge of the participants regarding OA and the treatment of it96-98. 
Obesity and knee OA are closely interrelated and often occur at the same time99. The effect sizes for 
weight loss in knee OA are small to moderate (Figure 6)88. Weight loss programs have typically 
been delivered as supervised sessions on a weekly basis for a range of 8 weeks to 2 years100-106. The 
strategies of the weight loss programs focused on how to reduce calorie intake using meal plans, 
reduced fat, sugar and portion sizes, meal replacements, and included behavioral modifications, 
self-monitoring, weight-loss goals, and maintenance of body weight when pre-defined goals were 
reached100-106. However, evidence for long-term maintenance of the weight loss achieved at short-
term is sparse87.  
A recent systematic review incorporating trial sequential analysis and network meta-analysis107 
concluded that sufficient evidence had accumulated in knee OA to show significant benefit of 
exercise over no exercise and that future trials were unlikely to change the conclusion. The effect 
sizes (Figure 6) for the efficacy of exercise to improve pain and functions illustrate that this is a 
very potent treatment of knee OA89. Similar effect sizes (p = 0.733) have been demonstrated when 
aerobic exercise (SMD: 0.67, focusing on improving cardiorespiratory fitness); resistance exercise 
(SMD: 0.62, focusing on improving muscle force); and performance exercise (SMD: 0.48, e.g. 
neuromuscular exercise, focusing on improving sensorimotor control and obtaining compensatory 
functional stability) have been compared across all RCTs in knee OA89. Even though this could lead 
one to conclude that the type of exercise is less important, it is reasonable to believe that different 
subgroups of patients (phenotypes) with knee OA would benefit from different types of exercise, 
which would thereby have the potential to attenuate the efficacy of exercise further108. This is 
supported by two recent studies109, 110 demonstrating that muscle strength109 and alignment110 
mediated the outcome of different exercise interventions. While intensity, duration of individual 
sessions, and patient characteristics (including radiographic severity) seem less important for the 
effects of exercise89, a prior meta-analysis showed that 12 or more supervised exercise sessions 
were approximately twice as effective as less than 12 sessions on both pain and function111. The 
importance of the number of supervised sessions for the efficacy has recently been confirmed by 
another meta-analysis89. After a supervised period, the exercise should be integrated into the daily 
life of the individual patient87. 
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1.4.2. Second line treatment of knee OA 
As illustrated in Figure 5, second line treatment includes a large variety of treatments, which is why 
the focus of this section will only be on some of those often applied in research and clinical practice 
and those relevant for this thesis. For a more comprehensive review, see McAlindon et al. 201488 
and Fernandes et al. 201387. 
OARSI recommends the application of biomechanical interventions if needed88. Two recent meta-
analyses have evaluated the effects of a valgus knee brace112 and lateral wedge insoles as a 
treatment for medial knee OA113. Moyer et al.112 demonstrated small to moderate effect sizes for 
both pain (SMD (95%CI) = 0.56 (0.03 to 1.09)) and function ((SMD (95%CI) = 0.48 (0.02 to 0.95)) 
when a valgus brace was compared to a control group not using a brace, while the effect was small, 
and only significant for pain, when compared to a control group that did not use an orthosis (SMD 
(95%CI) = 0.33 (0.08 to 0.58)). Parkes et al.113 found a small effect size for pain (SMD (95%CI) = 
1.20 (0.30 to 2.09)) when a lateral wedge insole was compared to a control group not using a 
wedge, while the effect was non-significant when compared to a neutral insole. It has been 
suggested that the non-significant effect when comparing a lateral wedge insole to a neutral insoles 
is based on the lack of individualization and/or medial arch support in the existing RCTs, 
potentially representing a key factor in the effect of insoles in medial knee OA114. 
As presented in Figure 6, acetaminophen (paracetamol) has small effect sizes for pain and function, 
suggesting that it is a useful short-term treatment88, 115. However, the risk of adverse events 
associated with paracetamol, including gastrointestinal adverse events and organ failure, has also 
been highlighted in two systematic reviews115, 116. Therefore, it is recommended that paracetamol is 
given for only short periods of time and in reduced doses88. 
Albeit more potent than paracetamol, oral NSAIDs have also demonstrated only small effect sizes 
(Figure 6)88. Due to the increased risk of serious gastrointestinal, cardiovascular, and renal adverse 
events compared to placebo117, OARSI recommends that they be used for  only  short periods of 
time and in reduced doses88. 
1.4.3. Total knee replacement (third line treatment) 
If first and second line treatment fail in improving symptoms, TKA is considered an effective 
treatment of knee OA118, replacing the joint surfaces with metal femoral and tibial prosthetic 
implants and a polyethylene insert between the two metal implants118, 119. The incidence of TKA in 
the US has increased markedly from 31.2 per 100,000 person-years in 1971–76 to 220.9 in 2005–
2008120, and is expected to increase by almost 700% by 2030121. Similarly, the incidence of the 
procedure has risen in the Scandinavian countries122 during the last decades, even though it seems to 
have leveled off in Denmark during recent years123. There are no published RCTs assessing the 
efficacy of TKA (Figure 6)124; however, one is underway in Denmark, finishing its long-term 
follow-up in January 2015125. Based on uncontrolled studies, TKA has been shown to improve pain, 
function and quality of life in the patient126, 127. However, the procedure is associated with an 
increased risk of adverse events and death, even when compared to unicompartmental knee 
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arthroplasty128, and imposes  a large financial burden on most health care systems, e.g. $10.4 billion 
in the US in 2008118. Traditionally, survival rates of the implant or time to revision, and not 
PROMs, have been the most important outcome measures for TKA registered in national 
arthroplasty registries118. The survival of the implant varies, but a systematic review demonstrated 
that 6.2% of patients (range 4.9% to 7.8%) had undergone revision after 10 years129, while a study 
from the Scandinavian countries showed that between 4% and 6% had undergone revision after 10 
years122. However, the number of patients dissatisfied with the outcome is higher, with 8% who had 
not undergone revision being dissatisfied130. Furthermore, a systematic review has demonstrated 
that 20% undergoing TKA experience only small or no improvements in pain outcome131, and more 
knee pain is known to be related to lower patient satisfaction132.  
1.5. Revision of total knee arthroplasty (TKA) and persistent post-operative pain 
Revision TKA (re-TKA) is defined as a second surgery needed to remove, add, or exchange one or 
more components of the primary TKA118. Pain, aseptic loosening, infection, instability, and stiffness 
following the primary TKA account for 80–90% of all revisions133-135. However, re-TKA is not as 
effective as the primary TKA118, the risk of re-revision being four to five times higher than the risk 
of revision after the primary TKA133 and patients being less satisfied after re-TKA compared to the 
primary TKA130. As the number of revision TKAs are expected to increase by more than 600% by 
2030121, primarily because of a  substantial increase in primary TKAs, the future economic burden 
of the procedure is evident136 and calls for a better understanding of risk factors and characterization 
of the patient population.   
Persistent post-operative pain (PPP) is a largely underestimated clinical problem known to affect 
between 5% and 85% of patients undergoing surgery depending on the type of surgery137, 138. PPP 
has previously been defined as pain after a surgical procedure lasting for at least 2 months138. 
However, this timeframe can vary depending on the type of surgery type 139. From studies of 
outcome in TKA, we know that pain levels off after 3 months140, which is why PPP in this thesis is 
defined as pain presenting for at least 3 months after surgery, with a change in pain characteristics 
following surgery, as recently recommended141. A systematic review pointed out that there is a wide 
variation in measures applied in the assessment of PPP after TKA and that many of these measures 
were unidimensional142 as opposed to current recommendations of a multimodal assessment of 
pain54, 143. Furthermore, evidence is missing concerning sensitization following re-TKA, even 
though this could help explain the poor pain outcome in some patients following surgery59. 
1.6. Treatment of sensitization 
A combination of strategies is recommended to be applied when treating sensitization in patients 
with persistent pain144. These strategies should target different mechanisms capable of desensitizing 
the central and peripheral nervous system using top-down (targeting the central nervous system) 
and bottom-up (targeting the peripheral nociceptive input) treatments144. Most current treatments of 
knee OA target the knee and adjacent structures, with little or no focus on central components of the 
pain (i.e. on top-down treatment)145, despite the apparent presence of central sensitization as 
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demonstrated in the section “ 1.3.2. Sensitization in knee OA”. On the other hand, studies 
demonstrating normalization of sensitization after total joint replacement (bottom-up treatment) in 
knee63 and hip OA82, 146 suggest that the sensitization, at least to some extent, arises and is 
maintained by peripheral input63. This is supported by two recent RCTs demonstrating that 
improvements in peripheral and central sensitization can be attained  through resistance exercises 
for the neck/shoulder in patients with neck/shoulder pain147 and through resistance and coordination 
exercises in patients with knee OA148, even though it can be questioned whether the effects of 
exercise are top-down (descending inhibitory mechanism) or bottom-up (the peripheral nociceptive 
input)144. 
Indications of modulation of sensitization in patients with knee OA have been found following a 
wide variety of non-surgical treatments targeting both bottom-up and top-down mechanisms148-153. 
The modulation have been found from exercise148, manual therapy149, 150, transcutaneous electrical 
nerve stimulation (TENS)151, opioids152, and coping skills training153. However, none of the studies 
combined the recommended treatments, and in most of the studies sample sizes were small, only 
small treatment effects were found, and/or patients were not randomized, questioning the validity of 
the findings. More research is needed regarding the investigation of the effects of non-surgical 
treatment on sensitization in knee OA73. 
1.7. Summary of background 
As proposed in Figure 1, pain and sensitization in OA-related pain can be considered a continuum 
going from few symptoms and low sensitization to severe pain and widespread sensitization, with, 
however, considerable variations between patients and subgroups within the populations. There is 
substantial evidence supporting the presence of pain and sensitization in knee OA70, 73, while the 
state of the nociceptive system in patients with PPP after re-TKA is unknown. Since 20% of 
patients undergoing a TKA have an unfavorable pain outcome131, knowledge of mechanisms (such 
as sensitization) involved in PPP is needed137, 138.  
Based on the available evidence, it is recommended that the treatment of knee OA includes 
education, exercise, and weight loss and can be supplemented with insoles and pain medication if 
needed87, 88 and that sensitization should also be treated using a multimodal approach144. However, 
little is known of the combined effects from the recommended non-surgical treatment on pain-
related measures and sensitization in knee OA, even though this could potentially prevent pain and 
sensitization from progressing and become severe and widespread73, 154.  
1.8. Aim of the PhD project 
1.8.1. General 
The overall aim of this thesis was to establish evidence concerning pain sensitization in patients 
with PPP after re-TKA, compare this to painful knee OA and explore whether the spreading of 
sensitization differs within the patient populations based on local knee pain sensitivity, and, lastly, 
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investigate whether multimodal non-surgical treatment improves outcomes of pain and sensitization 
in patients with knee OA. 
1.8.2. Specific 
The specific aims of the individual studies were: 
Study I: To compare patients with and without PPP after re-TKA utilizing a variety of experimental 
pain techniques for assessing 1) local sensitization, 2) widespread sensitization, 3) temporal 
summation, and 4) CPM. 
Study II: To compare sensitization (spreading of sensitization, facilitated temporal summation) in 
patients with knee OA and those suffering from PPP after re-TKA and in patients with low and high 
knee pain sensitivity.   
Study III: To investigate the combined efficacy of education, neuromuscular exercise, diet, insoles, 
and pain medication (the MEDIC treatment) in improving different pain-related measures and 
sensitization after 3 months compared to usual care (information and treatment advice) in patients 
with knee OA not eligible for TKA. 
1.9. Hypotheses 
Study I: Patients with PPP after re-TKA would have more pronounced peripheral and central 
sensitization than those without PPP after re-TKA. 
Study II: Patients with PPP after re-TKA and patients with high local knee pain sensitivity would 
have a more pronounced spreading of sensitization and temporal summation than patients with knee 
OA pain and patients with low local knee pain sensitivity. 
Study III: It was hypothesized that the MEDIC treatment would result in greater improvements in 
pain-related measures and sensitization than usual care at the 3-month follow-up. 
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2. Materials and Methods 
2.1. Design 
Study I and Study II were cross-sectional studies, while Study III was an ancillary report of the 3 
months results from a two arm parallel group assessor-blinded RCT (1:1 treatment allocation) for 
which the study protocol has previously been published155. The ancillary report was pre-defined in 
the statistical analysis plan made available before unblinding the data156. 
2.2. Study populations 
Study I 
Patients previously diagnosed with knee OA who had undergone TKA followed by a re-TKA using 
standard procedures157 with pain as one reasons for the re-TKA were invited to participate. In total, 
54 were screened and 40 patients agreed to participate; 20 with PPP in the revised knee and 20 
patients without pain in the revised knee matched on body mass and reasons for re-TKA (besides 
pain: loosening, infection, instability and stiffness). In the background, PPP was defined as pain 
present 3 months after surgery. However, since the pain has the potential to improve until 12 
months after TKA126, only patients with pain 12months after re-TKA were included in study I and II 
to ensure that possible improvements from surgery had been obtained. The participants were asked 
to refrain from using pain medication 24 h before the QST session. The study was conducted in 
accordance with the Helsinki Declaration and approved by the local ethics committee of the North 
Denmark Region (N-20100050). Oral and written information were provided to the participants, 
and written consent was obtained from all participants.  
Study II 
Fifty-three pain patients previously contacted regarding enrolment (some participating) in a study 
assessing sensitization in knee OA using QST61 and the 20 patients with PPP after re-TKA from 
study I participated. Raw data from a subset of patients published previously61 and parts from study 
I was included and reanalyzed according to the new protocol. The patients were divided into four 
groups according to the degree of their knee pain sensitivity (using PPTs) assessed at the most 
affected knee (see section 2.3. Procedure). The patients were asked to refrain from using any 
analgesics 24 h before the QST session. The study was approved by the local ethics committee of 
the North Denmark Region (N-20100050) and conducted in accordance with the Helsinki 
Declaration. Both oral and written information were provided to the patients, and written consent 
was obtained from all patients.  
Study III 
100 patients with radiographic and symptomatic knee OA found not eligible for TKA but 
experiencing more than mild functional limitations were enrolled. Patients were recruited from two 
specialized, public outpatient clinics at Aalborg University Hospital (Frederikshavn and Farsoe; 50 
patients from each clinic) between the 3rd of April 2012 and the 12th of July 2013. Major exclusion 
criteria were above 75 in the self-report questionnaire KOOS4 defined as the average score for the 
subscale scores for pain, symptoms, activities of daily living (ADL) and quality of life (QOL), 
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previous ipsilateral knee replacement and mean knee pain in the previous week greater than 60 mm 
on a 0-100 mm visual analogue scale (VAS). Table 1 includes the full list of inclusion and 
exclusion criteria. All patients gave informed consent before being enrolled and the study was 
conducted in accordance with the Helsinki declaration and approved by the local Ethics Committee 
of The North Denmark Region (N-20110085). Furthermore, the study was registered at  
ClinicalTrial.gov (NCT02091830). 
 
2.3. Procedures 
Study I 
Prior to the QST, the participants completed a questionnaire on demographics and clinical 
characteristics including questions on revision knee, other reasons for revision than pain, time 
between primary arthroplasty and first revision, number of revisions and total number of surgeries 
after their primary arthroplasty, duration of pain, and mean pain intensity in the revised knee before 
the primary arthroplasty, before the first revision and current knee pain measured on a 100 mm 
VAS with the endpoint descriptors of ‘no pain’ and ‘maximal pain’, respectively. Furthermore, the 
participants reported pain sites on a region-divided body chart, completed the WOMAC36, usage of 
pain medication, and the Knee Pain Map to evaluate their knee pain location and pattern56. The 
Knee Pain Map identifies areas of the knee that are painful and characterizes knee pain as localized 
(patellar, superior-medial, inferior-medial, medial joint line, superior-lateral, inferior-lateral, lateral 
joint line, or back of knee), regional (medial, lateral, patellar, or back of the knee), or diffuse, 
defined as unable to identify pain as localized or regional56.  
 
The participants rested in a comfortable recumbent position in a quiet, temperature-controlled room 
during the QST. The participants were carefully instructed in the QST methods before the 
experiment was initiated to make them familiar with the procedure. The data were collected by the 
same examiner (the author of this thesis). 
Inclusion Criteria Exclusion criteria  
Referred from primary care to an orthopedic 
surgeon in a public hospital in The North Denmark 
Region for evaluation of the need for total knee arthroplasty 
Previous ipsilateral knee arthroplasty 
Considered ineligible for a TKA by the surgeon Inflammatory arthritis 
Diagnosed with KOA using standing, weight-bearing 
knee radiographs (Kellgren-Lawrence score ≥1 on 
the original scale44, 45. 
Mean pain the previous week >60 mm on a 100 mm 
Visual Analogue Scale  
Aged ≥18 years Possible pregnancy or planning pregnancy 
KOOS4≤75 (the average score for four of the five 
Knee Injury and Osteoarthritis Outcome Score subscales 
covering pain, symptoms, activities of daily 
living and quality of life)34, 35. 
Inability to comply with the protocol 
Table 1. Inclusion and exclusion criteria in study III 
  
 
21 2. Materials and Methods 
Study II 
Prior to the QST, the patients completed a short questionnaire on demographics and clinical 
characteristics including questions on duration of knee pain and peak clinical pain intensity in the 
affected knee in the previous 24 h measured on a 100 mm VAS with the endpoint descriptors of ‘no 
pain’ and ‘maximal pain’, respectively. The patients rested in a comfortable recumbent position 
during the QST and were carefully instructed in the QST methods and made familiar with the 
procedures.  
 
Subgrouping of patients 
The pressure pain sensitivity from the knee region of the most affected knee 
(localized sensitization/local knee pain sensitivity) was used to subgroup the 
patients. PPTs from the knee region were assessed using a handheld pressure 
algometer (Figure 7; Algometer Type II, Somedic AB, Sweden). Pressure was 
applied perpendicular to the skin (30 kPa/s) with a 1 cm2 probe until the patient 
felt the pressure as pain and pressed a stop button attached to the handheld 
algometer after which the pressure was released. This defined the PPT. 
The average PPT for each patient was calculated from PPTs measured twice 
from eight sites in the knee region: 1) 2 cm distal to the inferior medial edge of 
patella; site 2) 2 cm distal to the inferior lateral edge of patella; site 3) 3 cm 
lateral to the midpoint on the lateral edge of patella; site 4) 2 cm proximal to the 
superior lateral edge of patella; site 5) 2 cm proximal to the superior edge of 
patella; site 6) 2 cm proximal to the superior medial edge of patella; site 7) 3 cm 
medial to the midpoint on the medial edge of patella; and site 8) at centre of 
patella61, 64 (Figure 8).  
 
In the OA group and re-TKA group the median knee PPT value for each group was used to 
subdivide into four groups based on the degree of localized sensitization: Group 1: OA patients with 
knee PPTs higher than the median PPT based on all OA patients. Group 2: OA patients with knee 
PPTs equal to or lower than the median PPT based on all OA patients. Group 3: re-TKA with knee 
PPTs higher than the median PPT based on all re-TKA patients. Group 4: re-TKA with knee PPTs 
lower than the median PPT based on all re-TKA patients.  
 
The median PPT was chosen as the cut-off point, since this divides the groups in equally sized 
subgroups with distinguishable degrees of local knee pain sensitivity.      
Study III 
Patients in need of evaluation for TKA in The North Denmark Region are referred by their general 
practitioner to an orthopedic surgeon at the outpatient clinics in Frederikshavn and Farsoe, 
Department of Orthopaedic Surgery, who specializes in TKAs. A standardized weight-bearing 
anterior-posterior knee x-ray is obtained on arrival158. 
Figure 7. Handheld 
pressure algometer 
Figure 8. Sites at knee 
where PPT was assessed  
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After the baseline measures were obtained, patients who agreed to participate in the RCT were 
assigned to one of two treatments: (i) the MEDIC-treatment, or (ii) usual care. Participants were 
reassessed 3 months after randomization (12-week follow-up). Both the baseline and 3-month 
follow-up were carried out at the Department of Occupational Therapy and Physiotherapy, Aalborg 
University Hospital, Denmark by the same outcome assessor, who was specifically trained in all 
aspects of the assessments in particular to obtain knowledge and experience in using the handheld 
algometer. Additional follow-ups were conducted 6 and 12 months and 2, 5 and 10 years after 
randomization (not part of this thesis).  
Randomization procedure and concealment of allocation 
Before initiating the trial, the schedule for randomization was randomly generated in permuted 
blocks using a computer. To control for variation in patient characteristics between the two clinics, 
the randomization was stratified according to the clinic (Frederikshavn or Farsoe). The allocation 
numbers were put in concealed, opaque C5 envelopes to conceal the outcomes of the 
randomization. In blocks of eight, these envelopes were placed in consecutively numbered opaque 
larger envelopes (seven larger envelopes in total for each clinic). A staff member, independent of 
this study, prepared the envelopes. These were only accessible by one research assistant at each of 
the respective clinics. A smaller envelope from the numbered larger envelopes were opened by the 
research assistant following the informed consent and completion of the baseline measures, after 
which the allocation was revealed to the participant. The smaller envelopes of the second larger 
envelope were added, when only two smaller envelopes were left in the first of the numbered larger 
envelopes. The last two of the smaller envelopes were added, when there were six smaller 
envelopes left in the sixth of the seven numbered larger envelopes at each clinic. 
Blinding 
The outcome assessor were blinded to group allocation, unaffiliated with the treatment sites, and not 
involved in providing the interventions. Furthermore, the statistician performing the statistical 
analyses was also blinded. The participants, the project physiotherapist and the project dietician 
delivering the interventions could not be blinded.  
2.4. Interventions 
Only study III included interventions. The participants in study III were randomized to MEDIC 
treatment or usual care. 
2.4.1. The MEDIC treatment 
The 12-week MEDIC treatment consisted of five components: education, exercise and insoles were 
prescribed to everyone in the MEDIC group, with weight loss and/or pain medication prescribed if 
indicated. The MEDIC treatment was delivered at Aalborg University Hospital, Denmark, by 
physiotherapists and dieticians trained in delivering the treatment to ensure proper standardization 
of the treatment. As recommended144, the aspects of the treatment targeted both bottom-up and top-
down mechanisms involved in the sensitization. 
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Patient education 
The patient education consisted of two 60-min sessions focusing on disease characteristics, 
treatment and assistance to support self-help by actively engaging the patients in the sessions and in 
the treatment of their knee OA. The education was delivered both orally and on a DVD to 
accommodate different learning styles among the patients and to give them the opportunity to 
review the information if needed. The patient education included in this study, in combination with 
neuromuscular exercise, has previously been tested in a similar population demonstrating feasibility 
and efficacy in reducing pain and improving function and quality of life96. 
Neuromuscular exercise 
The NEuroMuscular EXercise training program (NEMEX), previously found feasible in patients 
with moderate to severe knee OA159, was undertaken by patients twice a week for 12 weeks with 
each session lasting 60 min (Figure 9). Classes allowed for continuous admission to give new 
patients the opportunity to get support from more experienced patients. The exercise programme is 
based on neuromuscular and biomechanical principles and has different levels of difficulty for each 
exercise159. It aims at restoring neutral functional alignment (Figure 10) of the lower extremities by 
obtaining compensatory functional stability and improving sensorimotor control. Neuromuscular 
exercise is thus different from strength training (aimed at improving muscle force) and aerobic 
training (aimed at improving cardiorespiratory fitness). Each participant was monitored individually 
for pain intensity during the exercise session. Progression was allowed but only if the quality of the 
exercise could be maintained159. Details of the programme and individual exercises are provided 
elsewhere159. Following the 12 weeks of supervised exercise, there was a transition period of 8 
weeks, where the programme was increasingly performed at home to improve long-term adherence. 
 
Diet 
Patients with a Body Mass Index (BMI) ≥25 at baseline underwent a 12-week dietary weight loss 
programme consisting of four 60-min sessions aimed at reducing the body weight by at least 5% 
Figure 9. Examples from The NEuroMuscular EXercise 
training program (NEMEX). 
Figure 10. Appropriate position of knee over foot, 
i.e. joint in lower extremity well aligned. 
 24 Pain and sensitization in knee osteoarthritis and persistent post-operative pain 
and sustaining this weight loss to reduce symptoms102. The dietary intervention was based on 
principles from motivational interviewing with instructions and guidance relevant to the individual 
participant and their readiness to change and take action160. 
Insoles 
Patients in the MEDIC group received an individually fitted full-length Formthotics System insole 
with medial arch support (Foot Science International, Christchurch, New Zealand). Additionally, 
patients with a knee medial-to-foot position (the knee moves medially to the 2nd toe in three or more 
of five trials) using the valid and reliable single limb mini squat test161, had a 4° lateral wedge added 
to their insole. 
Medicine 
The patients were offered pain medication if the orthopedic surgeon considered it necessary for 
participation in the exercise classes. If no contraindications were evident, they were prescribed 1g 
paracetamol four times daily, 400 mg ibuprofen three times daily, and 20 mg pantoprazol daily. In 
order to supervise the use and indications of the medication, the prescription was reassessed every 3 
weeks. The patients were instructed to contact the physiotherapist if they questioned the 
continuation of the medicine during the 3-week period due to pain relief from the treatments given. 
Booster sessions 
After the 12-week MEDIC treatment and the following 8-week exercise transition period but prior 
to the 12-month follow-up, the physiotherapist contacted the patients monthly by telephone to 
support the continuation of exercise and physical activity, and to discuss issues and barriers against 
exercise that emerged after the supervised class-based exercise programme had stopped. 
Furthermore, patients undergoing dietary intervention received two additional 30-min telephone 
consultations with the dietician between the 3-month follow-up and the 12-month follow-up. 
2.4.2. Usual care 
Patients allocated to usual care were given two standardized information leaflets (also given to the 
MEDIC group). The first leaflet (four pages) holds information on knee OA with regard to etiology, 
symptoms, common functional limitations, recommended treatments and general advice on how to 
address the symptoms oneself.  The second leaflet (two pages) contains information on where in 
The North Denmark Region you can seek advice regarding treatment and general information on 
how to sustain a healthy lifestyle (with focus on diet, smoking, alcohol and physical activity).  
2.5. Outcomes 
See Table 2 for a list of all outcomes in this thesis. 
Study I 
The QST procedure consisted of three different psychophysical parameters: 1) Cuff algometry at 
the lower leg, 2) temporal summation of cuff-induced pain, and 3) CPM. The procedure was 
performed bilaterally and the sequence was randomized. 
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Cuff Algometry for Assessment of the Pain Sensitivity 
PPT and PTT were recorded by a computer-controlled cuff-algometer (Aalborg University, 
Denmark)162. A 13-cm wide tourniquet cuff (VBM, Germany) with an equal-sized proximal and 
distal chamber was wrapped around the lower leg at the level of the heads of the gastrocnemius 
muscle (Figure 11). The pressure was increased with a rate of 1 kPa/s and the maximal pressure 
limit was 100 kPa. The participants used an electronic VAS to rate their pressure-induced pain 
intensity and a button to release the pressure (Figure 12). The electronic VAS was sampled at 10 
Hz. Zero and ten cm extremes on the VAS were defined as “no pain” and as “maximal pain”, 
respectively. The participants were instructed to rate the pain intensity continuously on the 
electronic VAS from when the pressure was defined as pain (PPT) and to press the pressure release 
button when the pain was intolerable (PTT). The assessments were performed by inflation of the 
proximal chamber, the distal chamber, and both chambers simultaneously in a randomly generated 
sequence; each of the three conditions was repeated twice and a mean of the different parameters 
was applied in the statistical analysis. 
 
 
 
 
Temporal Summation of Cuff-induced Pressure Pain 
Temporal summation was assessed by the computer-controlled cuff-algometer (Aalborg University, 
Denmark)162. Ten cuff pressure stimuli (1s duration and 1s interstimulus interval) were delivered to 
the lower leg by simultaneous inflation of both cuff chambers at an intensity equivalent to the mean 
of the PPT and PTT recorded during the assessment of the pain sensitivity (Figure 11). In the period 
between stimuli a constant non-painful pressure of 5 kPa was kept ensuring that the cuff did not 
move. The participants rated their pain intensity continuously during the sequential stimulation on 
the electronic VAS without returning it to zero in-between the stimulations (Figure 12). The mean 
VAS scores during the 1s interstimuli interval after each of the 10 stimuli was extracted, normalized 
by subtraction of the mean VAS scores from the first stimulation. Two series of recordings were 
completed and the average was used in the statistical analysis.  
Conditioned Pain Modulation 
Experimental tonic pain (ischemia) was induced in the left arm by cuff-
induced pain (Figure 13; conditioning stimulation), and assessment of PPTs 
(test-stimulus) was done before, during and 5 min. after the conditioning 
stimulation using handheld pressure algometry (Figure 7). 
The conditioning stimulation was induced by constant cuff stimulation. A 7.5 
cm wide tourniquet cuff (VBM, Germany) was wrapped around the left arm 
with the lower rim of the cuff placed 3 cm proximal to the cubital fossa. The 
Figure 11. The tourniquet cuff wrapped around the 
lower leg. 
Figure 12. The electronic visual 
analogue scale. 
Figure 11. The 
tourniquet cuff used to 
induce tonic arm pain 
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computer-controlled cuff-algometer (Aalborg University, Denmark) maintained a constant pressure 
corresponding to a pain of 4 cm at the electronic VAS rated by the individual participant. If the 
cuff-induced pain did not reach 4 cm on the VAS scale, the participants were asked to do hand grip 
exercise until the pain intensity target was achieved. The test-stimulus (PPTs assessed using a 
handheld algometer) was applied, bilaterally, using the protocol described in section “2.3. 
Procedure”, at eight test sites in the knee region (Figure 8), one site at the tibialis anterior muscle 
(lower leg; 5 cm distal to the tibial tuberosity), and one site at the extensor carpi radialis longus 
muscle (forearm; 5 cm distal to the lateral epicondyle of the humerus)61. The average of two PPT 
measurements from all eight sites in the knee region, the lower leg, and the forearm were applied in 
the analysis of CPM61.  
Study II 
Spreading sensitization to pressure pain stimulation 
Bilaterally, PPTs were measured from the lower leg and the forearm61 using the same protocol as in 
study I. The PPT was measured twice at each site and the averages were used for further analysis.   
Temporal summation of pressure pain 
Temporal summation was assessed using a computer-controlled 
pressure algometer (Figure 14; Aalborg University, Aalborg, 
Denmark)163. The mechanical pressure stimuli were applied 
perpendicular to the skin surface using a circular aluminum 
footplate with a 1 cm2 padded contact surface fixed to the tip of the 
piston. Using recordings of the actual force the pressure stimulation 
was feedback controlled. The PPT was found by increasing the 
pressure until the patient defined the pressure as pain. At the level 
of the PPT, ten sequential pressure stimuli were applied to the 
most sensitive site in the knee region and to the lower leg (1 s 
duration and 1 s inter-stimulus interval). Between the individual pressure stimuli skin contact was 
kept by applying a constant force of 0.1 kg, which did not evoke pain. During the sequential 
stimulation the patients rated their pain intensity continuously on an electronic VAS where 0 cm 
indicated ‘no pain’, and 10 cm indicated ‘maximal pain’. The VAS signal for each stimulus was 
sampled by a computer at 200 Hz. The mean VAS scores during 1s after each stimulus were 
extracted and normalized by subtraction of the mean VAS score from the first stimulation. The sum 
of normalized VAS scores of two series of stimulations from each site was applied in the statistics 
(VAS sum; possible range 0-90).  
Study III 
Primary outcome 
The primary outcome was peak knee pain intensity in the previous 24h assessed on a 100 mm VAS 
with terminal descriptors of ‘no pain’ and ‘worst pain possible’. We chose peak pain intensity since 
it has been frequently applied in studies on sensitization in knee OA-related pain61, 64. The VAS is a 
measure of pain widely used in patients with knee OA that is valid, reliable and responsive55.  
Figure 12. Computer-controlled 
pressure algometry 
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Secondary outcomes 
All secondary outcomes were declared supportive of the primary outcome. 
Assessment of pain 
Pain intensity during function 
Knee pain intensity after 30 min of walking was assessed on a 100 mm VAS with terminal 
descriptors of ‘no pain’ and ‘worst pain possible’. Pain intensity after 30 min of walking was 
chosen, since it can serve as an indirect measure of how the knee pain affects function.  
Knee pain location and pattern 
Knee pain location and pattern in the most affected knee were assessed using the reliable 
interviewer-administered questionnaire Knee Pain Map previously applied in knee OA patients 
(described in section “2.3. Procedure”)56, 57. Since diffuse pain is indicative of a more progressed 
sensitization59, the results were dichotomized (diffuse pain in the most affected knee yes/no).  
Spreading of pain 
The patients were asked to shade body sites with pain in the previous 24 hours on a region-divided 
body chart (26 sites in total). The number of pain sites was applied to classify the spreading of pain 
as previously suggested in a large scale study on multisite pain58.  
Functional limitations 
This was evaluated using the subscale ADL (Function in daily living) from the KOOS34, 35, which is 
identical to the physical function subscale from the Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC)36.  
Usage of pain medication 
This was defined as any pain medication taken on a regular basis during the last week at baseline 
and the 3 months follow-up. The results were dichotomized (pain medication yes/no) due to non-
uniformity of the distribution of pain medication intake. 
Assessment of sensitization 
PPTs were measured bilaterally using the same protocol as in study I and study II at four sites at the 
knee (site 3, 5, 7 and 8 in Figure 8; localized/peripheral sensitization), at the lower leg 
(spreading/central sensitization), and at the forearm (spreading/central sensitization)61. One or two 
test assessments were performed at the dorsal aspect of the hand to ensure that the patient 
understood the procedure. PPTs were obtained twice at each site, and the mean of the two 
assessments were applied in the statistical analysis for the knee (a mean of all four sites), for the 
lower leg and for the forearm. The test procedure has previously been assessed in a test-retest 
reliability and agreement study with 20 patients with knee OA demonstrating intraclass correlation 
coefficients (2-way random-effects model, consistency-type) and 95% limits of agreement (95% 
LOA; presented as the difference between the mean difference and the upper and lower LOA) of 
0.84-0.91 and 199.6-434.0 kPa164 for the different test sites. The 95% LOA corresponds to the 
minimal detectable change (MDC)165 for the assessment method. 
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2.6. Statistics 
Study I 
Sample Size 
The sample size was calculated based on the pre-defined hypothesis (Patients with PPP have more 
pronounced sensitization than those without pain). With a standard deviation of 4 kPa, the sample 
size needed to detect a 4 kPa difference between groups in PPT (cuff algometry) at the lower leg 
(power of 80% and significance level at 0.05 (two-sided)) was 16 in each group. To account for 
missing data and potential hardware issues 20 were included in each group, which was also deemed 
adequate to find differences between groups in the other outcomes. 
Measure Study I Study II Study III 
Patient-reported    
Body sites with pain    
Current knee pain (VAS 0-100)    
Knee Pain Map (Pain location and pattern)    
KOOS ADL1    
Pain intensity after 30 min of walking (VAS 0-100)    
Peak pain intensity in the previous 24h (VAS 0-100)    
Usage of pain medication    
Duration of knee pain    
Quantitative sensory testing    
Computer-controlled algometry, temporal summation    
Conditioned Pain Modulation    
Cuff algometry, PPT    
Cuff algometry, PTT    
Cuff algometry, temporal summation    
Handheld algometry, PPT at the knee     
Handheld algometry, PPT at the lower leg    
Handheld algometry, PPT at the forearm    
Table 2. Overview of outcomes and other important measures in this thesis. 1KOOS ADL in paper I was 
calculated from WOMAC Function using the formula 100 – (raw function score x 100)/maximum function score. 
VAS = Visual Analogue Scale; KOOS = The Knee Injury and Osteoarthritis Outcome Score; ADL = Activities of 
Daily Living; PPT = Pressure Pain Threshold; PTT = Pain Tolerance Threshold. 
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Statistical analyses 
Data were assumed to be normally distributed; confirmed by visual inspection of Q-Q plots. To 
compare demographics and clinical characteristics between the two groups Pearson’s chi-square 
was used for gender, revision knee and pain medication, Fisher’s exact test for knee pain pattern, 
Mann Whitney U test for total pain sites and an independent samples t-test for the other 
characteristics. A three-way analysis of variance (ANOVA) was used to evaluate cuff algometry 
and temporal summation data with factors group (pain, no pain), side (revised, contralateral) and 
chamber (proximal, distal, both) or stimulation number (1-10). A repeated measures (RM) ANOVA 
was used to evaluate CPM with time (before, during, after conditioning stimulation) as the within-
subject factor and side (revised, contralateral) and pressure site (knee, TA, forearm) as the 
between-subject factors for both the pain group and the no pain group. Tukey HSD (for three-way 
ANOVA) or Bonferroni (for repeated measures ANOVA) were used as post hoc tests in cases of 
significant ANOVA factors or interactions. Gender and age was set as covariates in the between 
group ANOVA analyses to control for potential effects of these variables.  
Study II 
Sample Size 
The sample size was calculated based on the pre-defined hypothesis (Patients with PPP have more 
pronounced sensitization than those with knee OA). With a standard deviation of 100 kPa, the 
sample size needed to detect a 100 kPa difference between groups in PPT from the forearm (power 
of 80% and significance level at 0.05 (two-sided)) was 16 in each group. To account for the 
relatively large variation previously demonstrated in sensitization in patients with knee OA61, at 
least 50 patients with knee OA was needed to allow for subgroup analyses of the second pre-defined 
hypothesis (patients with high local knee pain sensitivity have more pronounced widespread 
sensitization than those with low local knee pain sensitivity). Therefore 53 patients with knee OA 
and 20 patients with PPP after re-TKA were included. 
Statistical analyses 
Confirmed by visual inspection of Q-Q plots data were normally distributed. A one-way ANOVA 
was used to evaluate peak clinical pain intensity in the previous 24h, PPT and temporal summation 
data with group (1-4) as a factor. Due to unequal sample size and unequal variance in the groups the 
adjusted F statistic, Brown Forsythe test was applied for PPT and temporal summation. Games-
Howell was used as post-hoc tests in cases of a significant ANOVA except for peak clinical pain 
intensity in the previous 24h, where Tukey-Kramer was applied due to equal variance but unequal 
sample size.  
Study III 
Sample Size 
The sample size was calculated based on the primary outcome (peak pain intensity). The sample 
size needed to detect a 10 point difference (standard deviation of 14) between groups in peak pain 
intensity was 41 patients in each group (power of 90 % and significance level at 0.05 (two-sided)). 
To account for possible TKA during follow-up and missing data, the drop-out rate was set to 20 % 
and a total of 100 patients were randomized. Due to the ancillary nature of this pre-specified 
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analysis the sample size was deemed adequate for the purpose of providing additional 
characterization of the treatment effects from the MEDIC treatment.  
Statistical analyses 
Since this was an ancillary analysis only patients with available data from both the baseline and 3 
months follow-up, who did not undergo TKA in the follow-up period, were included in the analyses 
and no adjustments for multiplicity were conducted as endorsed by The European Agency for the 
Evaluation of Medicinal Products when exploratory analyses are declared supportive166.  
A Student’s t-test was used to evaluate change in pain intensity, KOOS ADL and number of pain 
sites between and within groups. A three-way ANOVA was used to evaluate change in PPT from 
baseline to 3 months with the fixed factors group (MEDIC, usual care), site (knee, lower leg and 
forearm) and side (most affected, contralateral). The analysis was conducted both unadjusted and 
adjusted (baseline PPT, gender and age). Within-group changes from the treatment in PPTs were 
further assessed using repeated measures ANOVA with time (baseline, 3 months) as the within-
subject factor and site (knee, lower leg and forearm) and side (most affected, contralateral) as the 
between-subject factors for both the MEDIC group and the usual care group. The assumptions of 
homogeneity of variance were tested using Levene’s test (P>0.05) and the assumption of normal 
distribution was tested by visual inspection of Q-Q plots. In case of non-significant between-group 
findings a sensitivity-analysis was performed including only those participating in at least 75% of 
the exercise sessions. Tukey HSD was used as post hoc test in cases of significant ANOVA factors 
or interactions.  
The relative risks for usage of pain medication and diffuse pain was estimated and compared 
between groups using a Poisson regression model with a robust error variance for the confidence 
intervals167. 
The significance level for all studies was set at P<0.05 and all analyses were performed in either 
IBM SPSS Statistics (Version 19, 20 or 22, IBM Corporation, Armonk, NY, USA) or Stata 13 
(StataCorp, College Station, TX, USA). 
 
 
 
 
 
 
  
 
31 3. Summary of results 
3. Summary of results 
3.1. Study I: Widespread sensitization in patients with persistent pain after 
revision TKA 
Demographics and clinical characteristics are shown in Table 3. Figure 15 illustrates the difference 
in body sites with pain between groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient characteristics 
mean (SD) or n (%) 
Patients with pain (n=20)  Patients without pain (n=20) P value 
Age (years)  61.5 (7.9) 65.7 (5.9) 0.06 
Gender, n women 14 (70) 8 (40) 0.06 
Body Mass Index (kg/m2)  30.7 (5.5) 31.5 (4.0) 0.61 
Revision knee, n right 11 (55) 6 (30) 0.11 
Duration of pain before primary 
arthroplasty (months) 
66.9 (84.8) 36.1 (41.4) 0.15 
Total duration of knee pain (months)  167.0 (101.1) 64.3 (50.9) <0.001* 
Time between primary arthroplasty 
and first revision (months) 
43.2 (52.8) 25.4 (27.3) 0.18 
Knee pain before primary arthroplasty 
(mm)  
78.3 (17.1) 81.9 (18.8) 0.53 
Knee pain before first revision (mm) 64.6 (20.8) 55.9 (30.4) 0.30 
Current knee pain (mm) 49.7 (26.2) 0.0 (0.0) <0.001* 
WOMAC total (arbitrary unit) 46.2 (18.9) 11.2 (9.5) <0.001* 
KOOS ADL (arbitrary unit) 52.9 (22.8) 87.4 (12.1) <0.001* 
Number of surgeries after primary 
arthroplasty (revisions/total) 
1.4 (0.8) / 2.9 (2.5) 1.2 (0.7) / 1.4 (1.1) 0.41/0.03* 
Body sites with pain 5.9 (2.7) 3.0 (3.3) <0.001* 
Knee pain pattern, n diffuse 15 (75) 0 (0) <0.001* 
Using pain medication, n 18 (90) 5 (25) <0.001* 
Table 3. Demographics of patients in study I (n = 40). *= significant differences (p<0.05).   
Figure 13. Body sites with pain. Sites of the body where at least 25% (n=5) of the patients with pain (A) and without 
pain (B) after re-TKA reported pain. The right side of the body in the figures has been set as the side with re-TKA.  
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Pain sensitivity 
Cuff PPTs and PTTs were significantly lower in the group with pain after the re-TKA compared to 
the group without pain after re-TKA (ANOVA: F(1,220) > 15.6, P < 0.001; Figure 16).  
Temporal summation 
An interaction between group and stimulation number showed that the normalized VAS scores to 
sequential stimulation were significantly higher in the pain group compared to the no pain group for 
stimulation 4 to 10 (ANOVA: F (9,738) = 6.13, P < 0.001; Tukey: P < 0.05; Figure 17). 
Conditioned pain modulation 
In the pain group handheld algometry PPTs from the knee region, the TA, and the forearm were 
significantly reduced from baseline during the painful conditioning stimulation (ANOVA: F(1.446, 
164.830) = 8.248, P = 0.001; Bonferroni:  P < 0.001; Figure 2). In contrast, in the no pain group 
PPTs from all sites increased significantly from baseline during the painful conditioning stimulation 
(ANOVA: F(1.575, 170.071) = 33.1, P < 0.001; Bonferroni: P < 0.001; Figure 2). 
Figure 14. Cuff pressure pain thresholds and tolerances. Mean cuff pressure pain thresholds (A; PPT) and cuff pressure 
pain tolerances (B; PTT) in patients with (solid symbols) and without pain (open symbols) after re-TKA. PPTs and PTTs 
were assessed for the proximal, distal and both chambers with a cuff mounted at the lower leg of the leg with re-TKA and 
contralaterally. Significantly lower PPTs and PTTs were found in the pain group than in the pain free group (*, P < 0.001). 
Furthermore, significantly higher PTTs were found for the proximal chamber compared to both the distal and both 
chambers (#, P < 0.05). Error bars indicate SEM.  
Figure 15. Temporal summation. Mean VAS scores after 10 cuff pressure pain stimulations (temporal summation) in 
patients with (solid symbols) and without pain (open symbols) after re-TKA. VAS scores were normalized by subtraction 
of the VAS scores from the first stimulation and presented for the leg with re-TKA (A) and contralaterally (B). The pain 
group had significantly higher VAS scores than the pain free group for stimulations 4 to 10 (*, P < 0.05). Error bars 
indicate SEM.  
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3.2. Study II: Facilitation of sensitization in knee OA and persistent post-
operative pain 
Demographics and clinical characteristics are shown in Table 4. The VAS score of the peak pain 
intensity was not significantly different between groups (ANOVA: F(3,72) = 0.95, P > 0.4). As 
expected, the PPTs from the affected knee in group 1-4 were significantly different due to the 
subgrouping (ANOVA: F(3,40.4) = 83.3, P < 0.001; Games-Howell: P < 0.01). 
 
Spreading sensitization 
PPTs from the lower leg and the forearm in group 4 were significantly lower (more spreading 
sensitization) compared to lower leg and forearm PPTs in groups 1, 2, and 3; the lower leg and 
forearm PPTs in group 2 and 3 were significantly lower than the lower leg and forearm PPTs in 
group 1 (Lower leg: ANOVA: F(3,81.0) = 63.3; Forearm: ANOVA: F(3,78.6) = 45.3; P < 0.001; 
Games-Howell: P < 0.05; Figure 3).  
Temporal summation 
VAS sum at the knee and lower leg was significantly higher in groups 3 and 4 compared to the 
VAS sum in groups 1 and 2 (Knee: ANOVA: F(3,72.3) = 10.7; Lower leg: ANOVA: F(3,72.7) = 
11.3, P < 0.001; Games-Howell: P < 0.05; Figure 18). 
 
Patient characteristics 
mean (SD) or n (%) 
Group 1 (n=26)  Group 2 (n=27) Group 3 (n=10) Group 4 (n=10) 
Age (years)  64.1 (7.5) 61.4 (8.5) 61.4 (9.9) 61.5 (5.7) 
Gender, n women 10 (38) 15 (56) 7 (35)  7 (35) 
Body Mass Index (kg/m2)  28.9 (5.5) 28.3 (3.7) 29.3 (6.0) 32.1 (4.9) 
Peak clinical pain in previous 
24 h (mm) 
52.1 (29.1) 62.4 (26.0) 58.0 (23.8) 65.6 (22.3) 
Duration of knee pain (months)  86.6 (72.0) 89.1 (71.8) 152.2 (76.2) 181.8 (123.7) 
PPT knee (kPa) 702.7 (222.8) 331.5 (99.6) 227.2 (63.7) 130.9 (18.8) 
Table 4. Demographics of patients in study II (n = 73). ‘PPT’: Pressure Pain Thresholds measured using a handheld 
pressure algometer in the knee region of the affected knee. The patients were grouped according to sensitivity at the 
most affected knee determined using the median pressure pain thresholds (PPT) from eight test sites in the knee region. 
Group 1 (n=26): knee OA pain and low knee pain sensitivity. Group 2 (N=27): knee OA pain and high knee pain 
sensitivity. Group 3 (N=10): pain after re-TKA and low knee pain sensitivity. Group 4 (N=10): pain after re-TKA and 
high knee pain sensitivity.  
Figure 16. Temporal summation. Mean VAS scores after 10 pressure pain stimulations at the most sensitive site in 
the knee region (A) and at the lower leg (B). VAS scores were normalized by subtraction of the VAS scores from the 
first stimulation. Group 1 (n=26): knee OA pain and least knee pain sensitivity. Group 2 (N=27): knee OA pain and 
high knee pain sensitivity. Group 3 (N=10): pain after re-TKA and low knee pain sensitivity. Group 4 (N=10): pain 
after re-TKA and high knee pain sensitivity. Group 3 and 4 had significantly higher VAS sum than group 1 and 2 for 
both the knee and the lower leg (*, P < 0.05). Error bars indicate SEM.  
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3.3. Study III: The effects of non-surgical treatment on pain and sensitization in 
knee OA 
The flow of patients through the study is illustrated in Figure 19. Of the 654 patients assessed for 
eligibility, 553 were ineligible. Of the 101 who were eligible, one did not want to be randomized. In 
total, 100 were randomized with 43/50 (86%) in the MEDIC group and 46/50 (92%) in the usual 
care group completing the 3 months follow-up and included in the analysis. Characteristics of 
treatment groups at baseline are presented in Table 5. 
Between-group analyses 
Pain intensity 
There was a statistically significant difference in change (95 % CI) from baseline to 3 months of 
15.4 (2.6 to 28.2) in peak pain intensity (P = 0.019) and of 32.6 (18.1 to 45.0) in pain intensity after 
30 min of walking (P < 0.001) favoring the MEDIC group. 
Knee pain location and pattern 
There was no significant difference between treatment groups in the change in proportions with 
diffuse pain at 3 months compared to baseline. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Flow of patients in the study. K-L score = Kellgren-Lawrence score; KOOS4 = The average score 
for the subscale scores for pain, symptoms, activities of daily living and quality of life from the Knee injury and 
Osteoarthritis Outcome Score, VAS=Visual Analogue Scale. 
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Spreading of pain 
There was a statistically significant difference in change (95 % CI) from baseline to 3 months of 
0.86 (0.03 to 1.70) in number of sites with pain (P = 0.042) favoring the MEDIC group. 
Figure 20 illustrates the difference in body sites with pain at baseline and after 3 months in the 
MEDIC group and the usual care group.  
 
Patient characteristics 
Mean (SD) or n (%) 
MEDIC (n=50) Usual Care (n=50) 
Gender, n women 26 (52) 25 (50) 
Age (years) 64.8 (8.7) 67.1 (9.1) 
Body Mass Index (kg/m2) 30.6 (5.6) 29.4 (5.2) 
Bilateral knee pain 18 (36) 21 (42) 
Duration of knee symptoms   
     0-6 months 4 (8) 2 (4) 
     6-12 months 9 (18) 6 (12) 
     1-2 years 10 (20) 5 (10) 
     2-5 years 11 (22) 13 (26) 
     5-10 years 4 (8) 8 (16) 
    More than 10 years 12 (24) 16 (32) 
Radiographic knee OA severity (Kellgren-Lawrence)   
    Grade 1 7 (14) 11 (22) 
    Grade 2 13 (26) 15 (30) 
    Grade 3 13 (26) 10 (20) 
    Grade 4 17 (34) 14 (28) 
Peak pain intensity in the previous 24h (0-100) 60 (23) 56 (25) 
Pain intensity after 30 min walking (0-100) 62 (26) 47 (24) 
KOOS ADL 55.5 (17.1) 60.4 (16.4) 
Using pain medication, n 32 (64) 30 (60) 
Body sites with pain 3.2 (2.9) 2.8 (2.1) 
Knee pain pattern, n diffuse 34 (69) 26 (55) 
Table 5. Demographics of patients in study III (n = 100).  
Figure 18. Pain sites. Sites of the body where at least 10% of the patients in the MEDIC group (A) and in the usual care 
group (B) reported pain in the previous 24 hours. A black shade indicates that at least 10% reported pain at both baseline 
and the 3 months follow-up, while a grey shade indicates that at least 10% reported pain at baseline, but not at the 3 
months follow-up. The right side of the body in the figures has been set as the side mostly affected by knee osteoarthritis. 
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Functional limitations 
There was a statistically significant difference in change (95% CI) from baseline to 3 months of 
15.1 (7.8 to 22.5) in functional limitations (P < 0.001), favoring the MEDIC group. 
Usage of pain medication 
There was no significant difference between groups in the usage of pain medication at 3 months 
compared to baseline. 
Sensitization 
No statistically significant differences in changes in PPTs from baseline to 3 months were found 
between groups in the crude analysis (F(1,468) = 0.028, P = 0.868) or when adjusting for baseline 
PPT, age and gender (F(1,465) = 0.015, P = 0.902; Figure 4). 
 
Within-group analyses 
Within-group results are presented in Tables 3 to 5 in paper III. 
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4. Discussion 
4.1. Main Findings 
The aim of this thesis was to investigate pain and sensitization in patients with PPP after re-TKA, 
compare patients with PPP after re-TKA to patients with painful knee OA and explore whether the 
spreading of sensitization differs within the patient groups based on an evaluation of local knee pain 
sensitivity, and investigate whether a 3-month treatment program of education, neuromuscular 
exercise, weight loss, insoles, and pain medication improves pain and sensitization outcomes in 
patients with knee OA. Study I is the first study to investigate sensitization in patients with PPP 
after re-TKA, Study II is the first to compare spreading of pressure pain sensitization and temporal 
summation in patients with painful knee OA and patients suffering from PPP after re-TKA, and 
study III is the first to evaluate multiple pain-related measures, including sensitization, in a 
randomized setting in patients with knee OA. 
The thesis demonstrated that patients with PPP after re-TKA had significantly more pain sites and 
more pronounced pressure pain sensitivity at the lower leg and forearm (indicators of more 
pronounced widespread sensitization) compared to the patients without pain after re-TKA. 
Furthermore, the group with PPP demonstrated facilitated temporal summation of pain and 
impaired descending pain modulation, highlighting the importance of central mechanisms in the 
process of spreading pain sensitization. 
In patients with PPP after re-TKA temporal summation was more facilitated than it was in patients 
with knee OA with similar pain intensities. The same was found for spreading sensitization when 
re-TKA patients with high local knee pain sensitivity were compared to OA patients with high local 
knee pain sensitivity and re-TKA patients with low local knee pain sensitivity to OA patients with 
low local knee pain sensitivity. Furthermore, the spreading sensitization was more pronounced in 
patients with high local knee pain sensitivity compared to patients with low local knee pain 
sensitivity within the OA and re-TKA patients, respectively.  
The 3-month non-surgical treatment program was associated with greater improvements in pain 
intensity outcomes and in measures of the spreading of bodily pain and functional limitations, but 
not in sensitization, knee pain pattern, and usage of pain medication after 3 months compared to 
information and treatment advice in patients with knee OA not eligible for TKA. These findings 
confirm that pain has a multitude of facets, and that treatment results may differ depending on what 
pain-related measures are evaluated.  
4.2. Knee pain and sensitization in knee OA and persistent post-operative pain 
It is generally accepted in the scientific community that a nociceptive input, including surgeries 
such as TKA, changes pain processing in the peripheral and central nervous systems137, 168-174. Even 
though a RCT175 demonstrated a reduction in PPP as a result of preoperative treatment with 
pregabalin (a centrally acting drug) in patients with knee OA undergoing TKA, a recent review 
concluded that the current evidence is conflicting with regard to the efficacy of perioperative 
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pharmacological treatment on PPP172. Since 20% undergoing a TKA experience a medically 
unexplained unfavorable pain outcome131, this underlines the need for a better understanding of 
mechanisms, such as sensitization, involved in OA-related pain50 and PPP137, 138 to be able to target 
the treatment toward those mechanisms before TKA is considered, and peri- and postoperatively to 
prevent and/or treat PPP. This thesis contributes significantly to this understanding. 
4.2.1. Pain  
Comparing the peak pain intensity in the participants in study III (mean of 58 out of 100) to that in 
the participants in study II (mean of 62 out of 100) and the functional limitations in the participants 
in study III (mean of 58 out of 100) to those in participants in study I (mean of 53 out of 100), there 
seemed to be small if any differences between the population with PPP after re-TKA and the 
population with knee OA pain. However, as described in the background, inclusion of several 
different measures and thereby encompassing the complexity of pain54, also with regard to  PPP143, 
is recommended. Looking at the other measures related to pain, another picture emerges: body sites 
with pain (re-TKA: mean of 6; knee OA: mean of 3), knee pain pattern (re-TKA: 75% with diffuse 
pain; knee OA: 60 % with diffuse pain), duration of knee pain (re-TKA: mean of 14 years; knee 
OA: only 28% had had pain for more than  10 years), and pain medication usage (re-TKA: 90% 
were users; knee OA: 62 % were users) all indicated that the patients with PPP after re-TKA were 
more severely affected by the pain. Besides highlighting the importance of a multimodal pain 
assessment, this stresses the major clinical problem constituted by PPP after re-TKA. 
4.2.2. Pain sensitivity 
In persistent pain due to knee OA, localized sensitization together with widespread sensitization has 
been demonstrated61-63, 74-77. The studies in this thesis showed that similar factors are also important 
in patients with PPP after re-TKA and that they are more pronounced in patients with PPP as 
compared to patients with knee OA pain. Individuals with OA have lower PPTs in both the affected 
joint and at remote sites compared to pain-free participants as an indicator of spreading 
sensitization70. The studies in this thesis demonstrated that this was also the case with regard to PPP 
after re-TKA: pressure pain sensitivity at the lower leg was greater in both the revised and the 
contralateral leg than it was in pain-free patients after re-TKAs. The spreading of sensitization to 
the contralateral side has previously been demonstrated in knee OA using handheld pressure 
algometry61, 63, 74 and cuff algometry63; a phenomenon for which there can be several explanations. 
Firstly, it is likely that some of the participants had bilateral knee OA before undergoing the 
primary TKA and later revision and therefore still had symptoms in the contralateral knee. 
Secondly, it is possible that subclinical changes exist in the contralateral knee that affect the 
sensitization related to the contralateral side. Lastly, the chronic pain state could result in bilateral 
sensitization in the central nervous system, a notion supported by data from experimental 
inflammatory rat OA models showing that central changes occur in addition to the localized 
nociceptor sensitization176-179. Interestingly, study II showed increased pain sensitivity distant from 
the affected joint in response to mechanical stimuli at the lower leg and forearm in patients who had 
PPP after re-TKA compared to OA pain patients, indicative of a progression of sensitization at later 
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stages of the disease/treatment. A recent study supports this by demonstrating increased pain 
sensitivity to pressure, heat, and cold at the affected knee and forearm in patients with pain 1 year 
after TKA, with PPTs lower than those in the patients with knee OA in studies I and II but higher 
than those in the patients with PPP after re-TKA180. This spread of sensitization could ultimately 
lead to a situation whereby a local pain problem develops into regional or even widespread pain59, 63, 
as described in section “1.3.2. Sensitization in knee OA”. The present data from patients translate 
previous findings from animal studies showing enhanced responses to stimuli applied to sites 
adjacent and distant to a joint with ongoing nociceptive activity176. In rats with unilateral arthritis181 
and chronic polyarthritis182, spinal cord neurons with input from the joint become hyperexcitable, 
the neurons begin to display an increased responses to stimuli applied to regions adjacent to and 
distant from the joint, and the total receptive field can become enlarged. Secondary hyperalgesia 
due to joint nociception can last for several weeks, and this hypersensitivity is related to increased 
responses of spinal cord neurons to input from A- and C-fibers183.  
Surprisingly, the studies in this thesis also highlighted that not all patients with knee OA have 
increased pain sensitivity. In study III, the participants had PPTs from the knee, lower leg, and 
forearm (approx. 550, 590, and 400 kPa, respectively) that were significantly higher than the PPTs 
in patients with PPP after re-TKA in studies I/II (approx. 180, 190, and 150 kPa, respectively). 
However, a comparison of  PPTs found in  study III to those in pain-free subjects of comparable age 
and gender distribution from another study (approx. 600, 500, and 350 kPa, respectively)61 
illustrates that the similarities are apparent and supports the presence of subgroups with and without 
sensitization, potentially related to disease severity184, within the knee OA population as recently 
suggested73, 185.  
4.2.3. Temporal summation and conditioned pain modulation 
Temporal summation of pain has previously been demonstrated to be facilitated in patients with 
OA-related pain61, but also in other chronic musculoskeletal pain conditions such as whiplash 
associated disorder186 and fibromyalgia79. The studies in this thesis found a facilitated temporal 
summation of pain, mimicking the first part of the wind-up process, in patients with persistent pain 
after re-TKA compared to pain-free re-TKA patients and patients with symptomatic knee OA. 
Furthermore, a significant positive correlation (see papers I and II) between duration of knee pain 
and temporal summation was demonstrated. This confirms results from animals showing facilitated 
wind-up in experimental OA models187. Following strong, successive C-fiber stimulation of somatic 
nociceptive fibers in animals, a frequency-dependent enhancement in neuronal excitability occurs 
that outlasts the stimulation. In spinal cord neurons, repeated stimuli of this type result in an 
increase in the magnitude of the input from Aδ- and C-fibers188, often followed by the development 
of an after-discharge. Another contributing factor to the enhanced excitability is the postsynaptic 
action of neurotransmitters, such as substance P and glutamate, released by the repeated noxious 
stimuli 59. Wind-up starts and sustains central sensitization189, and a previous study has 
demonstrated that wind-up increases the receptive field area of dorsal horns in rats190: a feature of 
central sensitization59. Combined with the fact that both the revised and the contralateral side 
showed enhanced temporal summation compared to pain-free re-TKA patients and patients with 
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symptomatic knee OA, the findings in this thesis indicate that patients with pain after re-TKA have 
central sensitization191. Furthermore, although based on a cross-sectional analysis, study II suggests 
a worsening in the temporal summation of pain from knee OA pain to PPP after re-TKA, which 
needs further attention in future studies. This notion is supported by a study by Arendt-Nielsen et 
al.61 demonstrating that knee OA patients with higher pain intensities and longer pain durations had 
relatively more facilitated temporal summation compared to patients having lower pain intensities 
and shorter pain durations61. This is in line with the suggested spread of sensitization59, 63, further 
described in the section “1.3.2. Sensitization in knee OA”.  
It has been suggested that a dysfunctional CPM is important for the clinical manifestations of 
chronic pain at the same time making the entire neuroaxis more vulnerable to pain192. Study I 
demonstrated an impaired CPM, confirming previous findings in OA patients61, 63, 82. It has 
previously been demonstrated that the change in response to stimuli is more pronounced in 
spinalized animals, which highlights the influence of descending pathways193. During the 
development of joint inflammation, an increase in the tonic descending inhibition of neurons with 
input from the inflamed joint occurs194, 195. Whether continuous noxious stimuli from a painful joint 
lead to an increase in facilitatory and/or decrease in inhibitory mechanisms remains to be explored. 
It is however interesting that the group of patients with pain after re-TKA demonstrated increased 
pain sensitivity at the knee, lower leg, and forearm during the tonic arm pain. This suggests that the 
descending control acted as a promoting factor. A previous study in patients with severe knee OA63 
also found an increase in pain sensitivity at the knee during tonic arm pain, but not at the lower leg. 
This suggests that the CPM was further impaired in patients with PPP after re-TKA in study I, 
further emphasizing the importance of CPM as a complex interaction between facilitatory and 
inhibitory mechanisms. 
4.2.4. The generator of pain and sensitization in widespread sensitization 
Evidence from four controlled before-and-after reports has shown a normalization of the sensitized 
nociceptive system in patients with OA with no residual pain after pain-relieving joint replacement 
63, 82, 146, 196, suggesting that the sensitization arises and is maintained by peripheral input. In PPP after 
TKA and re-TKA, the environment in which the nociception can occur has changed due to the 
replacement of knee-related structures. However, due to the continuous pain and sensitization 
demonstrated in patients with PPP after re-TKA in studies I and II, it seems that there is still 
adequate peripheral drive to maintain the pain and sensitization. The retention of pain and 
sensitization after TKA and re-TKA can be related to peripheral input from non-surgically removed 
periarticular tissue such as adjacent muscles, connective tissue, and/or sensitization.  
In study II, the four groups had similar clinical pain intensities, underlining the notion that factors 
other than the severity of the pain were the cause of the differences found in the spread of 
sensitization and temporal summation. Both patients with knee OA and patients with PPP after re-
TKA with high knee pain sensitivity had more pronounced sensitization (lower PPTs distant from 
the affected knee and facilitated temporal summation) than those with low knee pain sensitivity. 
This highlights the importance of localized sensitization as an important generator of knee OA pain, 
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PPP, and central sensitization. This pain and sensitization could be caused and/or influenced by 
inflammation and neuropathic pain, e.g. due to nerve damage from surgery197, 198. Inflammation has 
recently been demonstrated to be associated with measures of sensitization in knee OA and may 
perhaps lead to increased pain sensitivity and pain intensity, thereby facilitating an increase in 
central sensitization 75, as supported by animal studies199, 200. Neuropathic pain has been reported in 
13% of patients with PPP after TKA201 and represents another driver of peripheral sensitization197. It 
is of course important to recognize that the ongoing pain and sensitization are probably caused and 
influenced by a complex interaction between several factors (other than inflammation and 
neuropathic pain) involved in the sensation of pain, including psychosocial and genetic factors12, 50, 
53, 137, 198. 
 
4.3. Non-surgical treatment of pain and sensitization in knee osteoarthritis 
As stated in the background, a combination of strategies should be used to treat pain and 
sensitization in patients with persistent pain, targeting both top-down (the central nervous system) 
and bottom-up (the peripheral nociceptive input) mechanisms144. Study III was the first study that 
combined treatments recommended for knee OA pain that applied both top-down and bottom-up 
approaches to target both pain and sensitization. 
4.3.1. The efficacy of non-surgical on pain 
The primary results from the RCT202 (the origin of  the data in study III) showed that the 3-month 
MEDIC-treatment155 resulted in greater long-term improvements in pain, function, and quality of 
life compared to usual care in knee OA patients seen in a secondary care setting. These results were 
confirmed by the ancillary results in study III, which was a study of the short-term efficacy of the 
MEDIC-treatment on a range of pain-related measures (different from those of the primary report). 
A comparison of  the short-term results from the MEDIC group in study III to those obtained in  the 
two previous RCTs investigating the long-term efficacy of a combination of at least two of the 
recommended treatments as compared with usual care for knee OA203, 204 shows some interesting 
differences. These two RCTs were the Enabling Self-Management and Coping of Arthritic Knee 
Pain Through Exercise (ESCAPE-knee pain) trial204 , which investigated the efficacy of combining 
exercise and education in older adults with knee pain recruited from primary care, and the Arthritis, 
Diet, and Activity Promotion Trial (ADAPT)203, which investigated the efficacy of combining 
exercise and weight loss in obese US community dwellers with knee OA. After 3 months, we found 
improvements in pain of 48% (peak pain intensity) and 56% (pain after 30min of walking) and in 
function of 32% in knee OA patients. These improvements are considerably larger than the short-
term results from the ESCAPE knee pain study, which found  improvements of approx. 23% in pain 
and 26% in function outcomes after 6 weeks204, and from the ADAPT trial that demonstrated 
improvements of approx. 25% in pain and 24% in function outcomes after 6 months203. While 
differences in the study populations can be part of the explanation for the larger improvements 
found in study III in this thesis, differences in the treatment protocols are more likely to be the 
cause. In addition to exercise, we included both education and diet, and insoles and analgesics if 
needed (as opposed to the ESCAPE and ADAPT trials). This could be crucial because weight loss 
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is an important contributor to the improvement in pain and function outcomes102 and the education 
taught the patients about the importance of the continuation of the treatment after the supervised 
period had ended and how to control and address OA problems on their own. Furthermore, some 
exercise-related causes could be an important explanation for the differences in efficacy. The 
ESCAPE knee pain trial comprised only 12 supervised sessions lasting 35-40 min without any 
transition period or booster sessions following the intervention204, while our exercise program 
comprised 24 supervised exercise sessions followed by a transition period, gradually increasing 
exercise at home, and monthly booster sessions to improve long-term adherence. A recent meta-
regression analysis demonstrated an increased efficacy with larger numbers of supervised 
sessions89, and a systematic review demonstrated beneficial long-term effects of booster sessions 
after the intervention period in patients with knee OA205. The ADAPT trial included more exercise 
sessions than our study (3 days/week of facility-based exercise for 4–6 months; 64% adherence to 
exercise and diet comparable to adherence in our study), but the exercise consisted of aerobic 
walking without any focus on alignment203. Our neuromuscular exercise program aimed to restore 
neutral functional alignment by improving sensorimotor control and obtaining compensatory 
functional stability. Varus-valgus control deficits and a lack of capacity to stabilize the joint are 
characteristic findings in patients with knee OA, indicating that neuromuscular exercise could be 
more beneficial than aerobic exercise206. However, while the evidence concerning the efficacy of 
non-surgical treatment on knee OA pain is strong87, 88, less is known about why exercise actually 
works207. Such information could help identify which patients would benefit from which type of 
exercise. 
Study III extends these findings by adhering to recommendations on addressing other aspects of the 
complexity of pain than pain intensity alone54, giving a comprehensive perspective on the effects of 
multimodal non-surgical treatment in patients with knee OA. The MEDIC group had a greater 
reduction in the number of body sites with pain compared to the usual care group. This could 
potentially be explained by systemic anti-inflammatory effects due to exercise208, as well as to 
improvements in well-being and other psychosocial components that have been demonstrated to 
result from exercise207 and/or the effects of education, i.e. teaching the patient about the etiology of 
pain and how to deal with it209. As mentioned, pain has been reported to spread over time59, the 
spread being influenced by both the intensity65 and duration66 of the pain, and pain in other body 
parts is associated with PPP after joint replacement201, 210, 211 and other surgical procedures212-215. The 
fact that knee pain increases the risk of developing persistent pain in other body parts over time 
further highlights the potential of multimodal non-surgical treatment for pain relief in patients with 
knee OA to prevent the pain from spreading. 
4.3.2. The efficacy of non-surgical treatment on sensitization 
Because the treatment given in the usual care group in study III closely resembles current practice 
in the treatment of knee OA patients not eligible for TKA, this group offered a useful standard 
against which to compare the efficacy of the treatment of the study population. However, while 
measures of localized sensitization and spreading sensitization improved in both groups, no 
significant differences in the efficacy of treatment on sensitization were found between the usual 
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care group and the MEDIC group. A recent RCT148 and a controlled before-and-after study76, both 
including a passive control group, found conflicting results with regard to the effect of exercise on 
sensitization in knee OA. Henriksen et al.148 demonstrated that 12 weeks of supervised exercise 
reduced pressure pain sensitivity, while Kosek et al.76 found no effects of exercise (average duration 
of 12 weeks) on pressure pain sensitivity. The within-group differences demonstrated in study III 
were not larger than the MDC for handheld algometry164, a method also applied in the other study 
demonstrating no effect of exercise on sensitization, which is why measurement uncertainty could 
be part of the explanation for the conflicting results. On the other hand, the significant differences 
demonstrated by Henriksen et al.148 were small, only borderline significant, and of questionable 
clinical relevance, and because the control group was asked to refrain from exercising, the results 
are also of little comparative relevance. 
4.3.3. Treatment of sensitization – equally relevant for all? 
From studies I and II and previous studies in knee OA61-63, 74-77, it is evident that peripheral and 
central sensitization are important and clinically relevant problems associated with the disease. It is 
a puzzle why the evidence supporting the efficacy of non-surgical treatment of pain and function in 
knee OA is unequivocal, while the evidence for the effects on sensitization remains conflicting. 
Although it is important to recognize that the research area of sensitization and treatment of 
sensitization is still in its infancy and in  need of more high quality studies, another explanation for 
the conflicting results could be the presence of subgroups of patients with OA with more 
sensitization and OA patients with less or no sensitization73, 185. Study II highlights that subgroups 
with more pronounced sensitization do exist among patients with knee OA and PPP after re-TKA, 
despite similar clinical pain intensities, while a recent study found that a subgroup with severe 
symptomatic knee OA but less severe radiographic knee OA had higher pain sensitivity than those 
with less severe symptomatic knee OA but severe radiographic severity216. Looking at studies using 
the questionnaire PainDETECT217 in patients with OA218-220, a measure used to indicate neuropathic 
pain, adds emphasis to the observation that the neuropathic component of OA pain is only present 
in some OA patients (5-50%). Albeit neuropathic pain is only an indirect indicator of sensitization73, 
this suggests that sensitization is only present in some knee OA patients.  
Sensitization may develop over time depending on disease severity and duration (depicted in Figure 
1) 59, 67. As presented in section “4.2.2. Pain sensitivity”, the PPTs found in study III are similar to 
those found in pain-free subjects of comparable age and gender distribution61, suggesting that the 
sensitization of the patients in study III may not yet have developed into a clinically relevant 
problem. This offers another explanation for the non-significant differences between groups, since it 
leaves little if any room for improvement in sensitization outcomes as a result of the MEDIC-
treatment. If the development of sensitization over time is mediated by disease severity, this would 
mean that treating the knee OA pain could represent a way of preventing sensitization, if treatment 
was initiated at an early stage before sensitization progressed.  
Regardless of whether sensitization is only found in some patients with knee OA and/or it is only 
present in those with more progressed symptom severity, non-surgical treatment of sensitization 
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should be targeted toward those actually affected by the problem, with the potential to desensitize 
the central nervous system by affecting both top-down and bottom-up mechanisms144, 145. Whether 
the multimodal MEDIC-treatment is efficacious in treating sensitization or should be supplemented 
with other treatments, such as centrally-acting drugs144, remains to be explored in future trials. 
4.4. Strengths and limitations 
The obvious limitation of both study I and study II is that they are cross-sectional, implying that no 
conclusions can be drawn on causality or the temporal changes in pain and sensitization. However, 
the novel findings provide useful insight relevant for future trials and clinical practice. Another 
potential limitation of study I and study II could be that the QST was restricted to mechanical, and 
to some extent chemical by ischemia, stimulation, even though a multimodal QST consisting of 
several stimulus modalities is recommended67, 72. On the other hand, since the studies investigated 
several different pain mechanisms (pain sensitivity, temporal summation, CPM, etc.) and several 
aspects of pain (intensity, duration, spreading, pattern, etc.) as has been recommended54, 67, 72, the 
outcome measures of study I and study II can actually be regarded as strengths instead of 
limitations.. Strength of studies I and II is their application of measures previously applied to other 
patient populations or with other purposes. Because of the consistency with previous results, this 
strengthens the validity of the findings.  
The MDC of the handheld pressure algometry applied in study III was relatively high, thereby 
affecting the conclusions that can be drawn on the effects of the treatment on sensitization. 
However, due to the ancillary nature of this study, the findings are not meant to give firm 
conclusions, but to be hypothesis generating for future confirmatory trials. Due to the multimodal 
setup of the treatment program in study III, it is unknown whether all components of the treatment 
are required for the improvements found in pain-related measures, and at the same time it makes it 
impossible to identify the efficacy of the individual treatment modalities alone. However, since the 
treatment program adheres to current guidelines on the treatment of knee OA87, 88 and is embedded 
in secondary health care, strengthening the generalizability of the findings, the strengths of the 
study are considered to outweigh the limitations.  
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5. Conclusions 
This thesis established that patients with PPP after re-TKA have prominent widespread 
sensitization, involving similar pain mechanisms as previously demonstrated in patients with knee 
OA. Furthermore, it was found that the spreading of sensitization and temporal summation were 
more pronounced in patients with PPP after re-TKA compared to patients with knee OA, despite 
similar clinical pain intensities, and that subgroups of patients with high knee pain sensitivity within 
the population of PPP and knee OA patients are more affected by spreading sensitization than those 
with low knee pain sensitivity. Lastly, the thesis demonstrated that a multimodal non-surgical 
treatment consisting of education, neuromuscular exercise, diet, insoles, and pain medication 
resulted in greater improvements in pain intensity, spreading of pain, and functional limitations 
outcomes than did usual care in patients with knee OA not eligible for TKA, while no between-
group differences were found in peripheral or central sensitization.  
5.1. Implications 
It is well known in the clinical setting that the pain in patients with knee OA and PPP after TKA 
and re-TKA becomes more and more complex if not treated successfully. The findings in this thesis 
support this and suggest some important clinical implications:  
1) The primary TKA and subsequent revisions should only be carried out if a potential involvement 
of peripheral and central pain mechanisms is either treated concurrently or, at best, before even the 
surgical procedure is considered.  
2) Furthermore, the treatment of pain and sensitization should comprise a combined, individualized 
early-stage treatment program addressing both peripheral and central components of the pain, with 
the potential to lessen pain and the spreading of pain and sensitization in those affected by the 
problem. 
5.2. Future perspectives 
The research area of sensitization, PPP after re-TKA, and treatment of sensitization in knee OA and 
PPP is still in its infancy, mostly consisting of cross-sectional studies and small, exploratory 
longitudinal studies221. Further large-scale prospective cohort studies identifying predictors (such as 
the QST applied in this thesis) of PPP and diagnostic decisions trees are needed to enhance the 
understanding of the area221, 222. Furthermore, high quality RCTs investigating the efficacy of non-
surgical and surgical treatment of pain and sensitization in knee OA would support clinical 
guidelines and improve the treatment of the patients124, 154, with the potential to reduce the growing 
burden of OA. 
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6. English Summary 
Osteoarthritis (OA) is an increasingly prevalent disease with substantial impact on those affected by 
it and on society. Knee OA, one of the most prevalent of all types of OA, is characterized by failed 
regeneration of joint damage, resulting in pain and functional limitation for the patient. Persistent 
post-operative pain (PPP) is a largely underestimated clinical problem known to affect between 5% 
and 85% of patients undergoing surgery. The pathophysiology of OA pain and PPP remains poorly 
understood, but a mechanism-based understanding is widely accepted and provides a basis for the 
understanding of pain. Peripheral and central pain sensitization have been demonstrated as 
prominent mechanisms influencing the pain in knee OA, while the state of the nociceptive system in 
patients with PPP after revision of total knee arthroplasty (re-TKA) is unknown. Since 20% 
undergoing a TKA have an unfavorable pain outcome, knowledge about mechanisms, such as 
sensitization, involved in the PPP are needed. It is recommended that the treatment of knee OA 
includes education, exercise, and weight loss, supplemented with insoles and pain medication if 
needed, and that sensitization should also be treated using a multimodal approach. However, little is 
known of the combined effects from the recommended treatments on pain-related measures and 
sensitization in knee OA, even though this could potentially prevent pain and sensitization from 
progressing and become severe and widespread.  
The overall aim was to investigate pain sensitization in patients with PPP after re-TKA (study I), 
compare this to painful knee OA and explore whether the spreading of sensitization differs within 
groups based on an assessment of local knee pain sensitivity (study II), and investigate whether 
multimodal non-surgical treatment improves pain and sensitization in knee OA (study III). 
Study I, a cross-sectional study, included 40 patients who had undergone re-TKA: 20 with PPP in 
the revised knee and 20 patients without PPP. Pain sensitization was assessed using the following 
measures: spreading of pain (number of body sites with pain), pressure pain threshold (PPT) and 
pressure pain tolerance (PTT) at the lower leg (cuff algometry), temporal summation of pain at the 
lower leg (recordings of the pain intensity on a visual analog scale (VAS) during 10 repeated cuff 
pressure stimulations), and conditioned pain modulation (CPM: tonic arm pain by cuff pressure 
stimulation and assessment of PPTs at the knee, leg, and forearm using handheld pressure 
algometry). Participants with PPP after re-TKA compared to participants without demonstrated 
significantly more pain sites (P = 0.004), decreased cuff PPTs and PTTs at the lower leg (P < 
0.001), facilitated temporal summation (P < 0.001), and impaired CPM (P < 0.001).  
Study II, a cross-sectional study, included 53 patients with painful knee OA and the 20 patients with 
pain after re-TKA from study I. Median PPTs assessed at the most affected knee (localized 
sensitization) were used to subgroup the patients: group 1: OA and low knee pain sensitivity; group 
2: OA and high knee pain sensitivity; group 3: re-TKA and low knee pain sensitivity, group 4: re-
TKA and high knee pain sensitivity. Peak pain intensity in the previous 24 h was assessed using a 
VAS. Pain sensitization was assessed using bilateral PPTs measured from the lower leg and forearm 
using handheld algometry (spreading sensitization). Furthermore, the pain intensities evoked by 10 
repeated pressure pain stimuli from computer-controlled pressure algometry (temporal summation) 
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at the knee and lower leg were assessed on an electronic VAS. The peak pain intensity was not 
significantly different between groups (P > 0.40). The PPTs from both lower leg and forearm were 
significantly lower in group 4 compared to groups 1, 2, and 3 and in groups 2 and 3 compared to 
group 1 (P < 0.05). Temporal summations from the knee and lower leg were significantly facilitated 
in groups 3 and 4 compared to groups 1 and 2 (P < 0.05). 
Study III was an ancillary report of the 3-month results from a two-arm parallel group assessor-
blinded randomized controlled trial with 100 participants that compared the efficacy of a 3-month 
treatment program consisting of education, neuromuscular exercise, diet, insoles, and pain 
medication (the MEDIC-treatment) to two leaflets with information and treatment advice (usual 
care) in patients with knee OA not eligible for TKA (Trial registration: clinicaltrials.gov 
NCT01535001). The primary outcome was peak pain intensity in the previous 24 h (VAS 0-100). 
Secondary outcomes included peripheral and central sensitization assessed at the knee, the lower leg 
and forearm (PPT from handheld pressure algometry), pain intensity after 30 min of walking (VAS 
0-100), pain location and pattern (Knee Pain Map), spreading of pain (body sites with pain), and the 
usage of pain medication (pain medication during the last week due to knee yes/no). Furthermore, 
functional limitations were assessed using the subscale Activities of Daily Living from the Knee 
Injury and Osteoarthritis Outcome Score. The MEDIC group had a mean improvement (95% CI) in 
outcome with regard to peak pain intensity from baseline to 3 months that was 15.4 (2.6 to 28.2) 
larger (P = 0.019) than in the usual care group. Furthermore, the improvements in outcome were 
larger in the MEDIC group in pain intensity after walking, in the number of body sites with pain 
and functional limitations (P < 0.05). There was no difference in the change in sensitization from 
baseline to 3 months between groups (P > 0.05), but sensitization improved in both groups (P < 
0.05). 
This thesis established that patients with PPP after re-TKA have prominent widespread 
sensitization, involving pain mechanisms similar to those previously demonstrated in patients with 
knee OA. Furthermore, it was found that spreading sensitization and temporal summation were 
more pronounced in patients with PPP after re-TKA compared to patients with knee OA, despite 
similar clinical pain intensities, and that subgroups of patients with high knee pain sensitivity within 
the population of PPP and knee OA are more affected by spreading sensitization than those with 
low knee pain sensitivity. Lastly, the thesis demonstrated that a multimodal non-surgical treatment 
program consisting of neuromuscular exercise, patient education, diet, insoles, and pain medication 
resulted in greater improvements in outcome with regard to pain intensity, spreading of pain, and 
functional limitations than usual care in patients with knee OA not eligible for TKA, while no 
between-group differences were found with regard to change in peripheral or central sensitization. 
The results of the thesis suggest that: 
1) Primary TKA and subsequent revisions should only be carried out if a potential involvement of 
peripheral and central pain mechanisms is either treated concurrently or, at best, before even 
considering the surgical procedure.  
2) The treatment of pain and sensitization should comprise a combined, individualized early-stage 
treatment addressing both peripheral and central components of the pain, with the potential to lessen 
pain and the spreading of pain and sensitization in those affected. 
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7. Danish Summary 
Titel: Smerte og sensitisering ved knæartrose og vedvarende smerte efter operation 
Forekomsten af artrose (slidgigt) er kraftigt stigende og lidelsen har en omfattende betydning for 
dem, der er påvirket af den, og økonomisk for samfundet. Knæartrose, en af de hyppigst 
forekommende typer af artrose, er karakteriseret ved en forfejlet genopbygning af ledstrukturer 
medførende smerte og nedsat funktion hos patienten. Vedvarende smerte efter operation (PPP) er et 
meget undervurderet klinisk problem, der påvirker mellem 5% og 85% af patienter, som gennemgår 
operation af den ene eller anden slags. Forståelsen for patofysiologien forbundet med artrosesmerter 
og PPP er fortsat begrænset, men en mekanismebaseret tilgang er bredt accepteret og anbefalet for 
at forbedre forståelsen af smerten i fremtiden. Perifer og central smertesensitisering har vist sig at 
være fremtrædende mekanismer influerende på smerten hos patienter med knæartrose, mens 
smertesystemet tilstand hos patienter med PPP efter revision af kunstigt knæled (re-TKA) endnu 
ikke er kendt. Da 20% som gennemgår en KK ikke opnår en smertereduktion, er der behov for en 
bedre forståelse for de mekanismer, såsom sensitisering, der er involveret i PPP. Det anbefales, at 
behandlingen af knæartrose indeholder uddannelse, træning og vægttab, samt at denne behandling 
kan suppleres med såler og smertestillende medicin ved behov. På samme måde anbefales det, at 
sensitisering behandles med en multimodal behandling. Der mangler dog fortsat viden om den 
kombinerede effekt af de anbefalede behandlinger på smerterelaterede mål og sensitisering hos 
patienter med knæartrose, selvom det potentielt set kan forhindre smerte og sensitisering fra at 
forværres og spredes til andre dele af kroppen. 
Det overordnede mål med denne afhandling var at undersøge sensitisering hos patienter med PPP 
efter re-KK (studie I), sammenligne dette med smertefuld knæartrose og undersøge om spredningen 
af sensitiseringen adskilte sig indenfor patientgrupperne på baggrund af smertesensitiseringen i det 
mest påvirkede knæ (studie II), og undersøge om multimodal ikke-kirurgisk behandling forbedrer 
smerte og sensitisering (studie III). 
Studie I var en tværsnitsundersøgelse af 40 patienter som havde gennemgået re-TKA; 20 med PPP 
og 20 uden PPP. Smertesensitisering blev undersøgt med de følgende mål: spredning af smerten 
(antal steder i kroppen med smerte); tryksmertetærskler (PPT) og tryktolerancetærskler (PTT) på 
underbenet (manchetalgometri); temporal summation på underbenet (måling af smerteintensiteten 
på en visuel analog skala (VAS) under 10 gentagne manchettryk); og betinget smertemodulering 
(CPM; tonisk armsmerte fremkaldt ved manchettryk og samtidig undersøgelse af PPT på knæet, 
underbenet og underarmen vha. håndholdt trykalgometri). Sammenlignet med deltagere uden PPP 
havde deltagere med PPP: flere steder med smerte (P = 0,004), reducerede PPT and PTT (P < 
0,001), faciliteret temporal summation (P < 0,001), og svækket CPM (P < 0,001).  
Studie II var en tværsnitsundersøgelse med 53 patienter med knæartrose og de 20 patienter med 
smerte efter re-TKA fra studie I. Median PPT fra det mest påvirkede knæ (lokaliseret sensitisering) 
blev anvendt til at subgruppere patienterne: gruppe 1: artrose og lav smertesensitisering i knæet; 
gruppe 2: artrose og høj smertesensitisering i knæet, gruppe 3: re-TKA og lav smertesensitisering i 
knæet; gruppe 4: re-TKA og høj smertesensitisering i knæet. Maximal smerte i knæet de sidste 24 
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timer blev undersøgt vha. VAS. Smertesensitisering blev undersøgt vha. bilaterale PPT fra 
underben og underarm vha. håndholdt algometri (spredning af sensitisering). Desuden, blev smerten 
fremkaldt ved 10 gentagne stimulationer fra et computer-kontrolleret trykalgometer (temporal 
summation) på knæet og underbenet undersøgt med en elektronisk VAS. Smerteintensiteten var 
ikke forskellig mellem grupperne (P > 0,40). PPT fra underben og underarm var lavere i gruppe 4 
sammenlignet med gruppe 1-3 og i gruppe 2 og 3 sammenlignet med gruppe 1 (P < 0,05). Temporal 
summation var mere faciliteret i gruppe 3 og 4 sammenlignet med gruppe 1 og 2 (P < 0,05). 
Studie III var en analyse af resultaterne efter 3 mdr. i et parallelt, to-armet, undersøger-blindet 
randomiseret, kontrolleret studie med 100 deltagere, der sammenlignede effekten af 3 mdr. 
behandling bestående af uddannelse, neuromuskulær træning, diæt, såler og smertestillende 
(MEDIC-behandlingen) med to brochurer med information og behandlingsanbefalinger 
(standardbehandling) hos patienter med knæartrose, som ikke var kandidater til en TKA 
(clinicaltrials.gov NCT01535001). Primær måleparameter var maximal smerteintensitet i knæet de 
sidste 24 timer (VAS 0-100). Sekundære måleparametre var perifer og central smertesensitisering 
undersøgt på knæet, underbenet og underarmen (PPT med håndholdt trykalgometri), 
smerteintensitet efter 30 min. gang (VAS 0-100), smerteplacering og –mønster (Knee Pain Map), 
spredning af smerte (antal steder i kroppen med smerte), forbrug af smertestillende medicin pga. 
knæ (ja/nej) samt nedsat funktionsniveau (subskalaen Funktion i dagligdagen fra the The Knee 
Injury and Osteoarthritis Outcome Score). MEDIC-gruppen havde en middelforbedring (95% CI) i 
maximal smerte fra baseline til 3 mdr. som var 15,4 (2,6 til 28,2) større (P = 0,019) end gruppen, 
der modtog standardbehandling. Desuden havde MEDIC-gruppen større forbedringer i smerte efter 
gang, antal steder i kroppen med smerte og funktionsniveau (P < 0,05). Der var ingen forskel i 
ændring i sensitisering mellem grupperne (P > 0,05), dog forbedredes den i begge grupper (P < 
0,05). 
Denne afhandling påviste at patienter med PPP efter re-TKA har en fremtrædende udbredt 
sensitisering involverende tilsvarende smertemekanismer som tidligere påvist hos patienter med 
knæartrose. Derudover viste afhandlingen, at spredningen af sensitisering og temporal summation 
var mere udtalt hos patienter med PPP efter re-TKA sammenlignet med knæartrose, på trods af 
lignende smerteintensitet, samt at subgrupper med høj smertesensitisering i knæet er mere påvirket 
af spredning af smerte end dem med lav smertesensitisering. Endelig, viste afhandlingen at 
multimodal ikke-operativ behandling medførte større forbedringer i smerteintensitet, spredning af 
smerte og funktionsniveau end standardbehandling hos patienter med knæartrose, der ikke er 
kandidater til TKA, mens der ingen forskel var mellem grupperne i ændring i perifer og central 
sensitisering. 
Afhandlingens resultater antyder at: 
1) Den første TKA og efterfølgende revisioner skal kun udføres, hvis en involvering af perifer og 
central sensitisering behandles samtidig, eller, endnu bedre, før kirurgien overvejes. 
2) Behandling af smerte og sensitisering bør indeholde en tidlig, individualiseret, multimodal 
behandling fokuserende på både perifere og centrale komponenter af smerten. Dette har potentialet 
til at forbedre smerte og sensitisering hos dem, der er påvirket af det. 
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